Autoimmune diseases (ADs) represent a broad spectrum of chronic conditions that may afflict specific target organs or multiple systems with a significant burden on quality of life. These conditions have common mechanisms including genetic and epigenetic factors, gender disparity, environmental triggers, pathophysiological abnormalities, and certain subphenotypes. Atherosclerosis (AT) was once considered to be a degenerative disease that was an inevitable consequence of aging. However, research in the last three decades has shown that AT is not degenerative or inevitable. It is an autoimmune-inflammatory disease associated with infectious and inflammatory factors characterized by lipoprotein metabolism alteration that leads to immune system activation with the consequent proliferation of smooth muscle cells, narrowing arteries, and atheroma formation [4].

Both humoral and cellular immune mechanisms have been proposed to participate in the onset and progression of atheromatous lesions [5].

In recent years, many reports have focused on the immunological background of AT, and there is no longer any doubt that it shares several autoimmune pathways [6, 7]. Therefore, it is not surprising to find an accelerated AT in quite a lot of ADs. Several risk factors, known as classic risk factors, have been described. Interestingly, the excessive cardiovascular events observed in patients with ADs are not fully explained by these factors. Several novel risk factors contribute to the development of premature vascular damage. In this review, we discuss our current understanding of how traditional and nontraditional risk factors contribute to the pathogenesis of CVD in AD.
autoimmunity. All of these pathways may possibly converge into a shared proatherogenic phenotype [16]. While ADs are characterized by a high degree of cardiovascular disease (CVD), there are several subphenotypes such as arterial hypertension (HTN); coronary artery disease (CAD): angina, ischemic heart disease (IHD), and myocardial infarction (MI); congestive heart failure (CHF); peripheral vascular disease (PVD); left ventricular diastolic dysfunction (LVDD); cerebrovascular disease (cerebrovascular accidents (CVAs); transient ischemic attacks (TIAs)); thrombosis: deep vein thrombosis (DVT), pulmonary embolism (PE); and subclinical AT.

In this paper, we discuss our current understanding of how traditional and nontraditional risk factors contribute to pathogenesis of CVD in ADs. It has become evident over the last few years that some ADs are characterized by common pathogenic mechanisms and high rates of morbidity and mortality that are mainly CVD-related. The increased CV mortality in the 3 rheumatic disorders studied the most (i.e., RA, systemic lupus erythematosus (SLE), and antiphospholipid syndrome (APS)) appears to be caused by vascular damage secondary to accelerated AT. However, the burden of CV involvement in other ADs (Sjögren’s syndrome (SS) and systemic sclerosis (SSc)) appears to be lower and it is characterized by specific risk factors in addition to those shared with the general population.

2. Methods

Studies were identified via a MEDLINE search using the following medical subject heading (MeSH) terms: “Arthritis, Rheumatoid” OR “Lupus Erythematosus, Systemic” OR “Antiphospholipid Syndrome” OR “Sjögren’s Syndrome” OR “Scleroderma, Systemic” AND “Cardiovascular Diseases.” Each group was cross-referenced with the following MeSH terms/keywords: “risk factors,” “traditional risk factors,” “classic risk factors,” “nontraditional risk factors,” and “novel risk factors.” Each term was counted for the greatest number of results. Limits regarding language (i.e., English), age (i.e., adults), and humans were taken into account. Assessment for inclusion of studies was done independently by two blinded reviewers (JAA-LMS). Disagreements between them were resolved by consensus using predefined eligibility criteria, from inception up to February 2014.

2.1. Study Selection, Data Extraction, and Quality Assessment. Abstracts and full-text articles were reviewed in search of eligible studies. A study was included if (a) the abstract was available, (b) it contained original data, (c) it used accepted classification criteria for each AD, (d) it measured CV risk factors, and (e) it examined clinical endpoints. Articles were excluded from the analysis if they dealt with juvenile pathologies or were done on animal models. Studies were also excluded if they were reviews or case reports, if they discussed topics not related to CVD in AD, if they did not meet the inclusion criteria, if they had insufficient data, or if they had results that showed lack of statistical significance. Likewise, the two blinded reviewers (JAA, LMS) looked for duplicates, excluded them, and organized selected articles. Only novel and classic risk factors [14, 15] with statistical significance were included.

3. Results

There were 6,324 articles identified in PubMed. Of these, 5,800 were identified as duplicates, lacking data or significant statistical associations. A total of 524 full-text articles were assessed for eligibility. Only 322 articles were included for methodological analysis. Finally, 168 articles that had interpretable data and fulfilled the eligibility criteria were included. Several traditional cardiovascular risk factors such as dyslipidemia, hyperhomocysteinemia, smoking, and T2DM had been reported. Many studies were associated with nontraditional risk factors such as genetic markers, autoantibodies, duration of the diseases, markers of chronic inflammation, polyautoimmunity, and familial autoimmunity. These factors and their associations are depicted in Tables 1, 2, 3, 4, and 5 and in Figures 1 and 2.

3.1. Rheumatoid Arthritis. A broad spectrum of subphenotypes and mortality due to CVD, including stroke, HTN, IHD, intima-media thickness (IMT), CAD, MI, PVD, thrombosis, and LVDD were described in RA, and the general prevalence range is 30%–50% [17–26]. Table 1 shows the main traditional and nontraditional risk factors associated with CVD in RA, and Figure 1 exemplifies these associations.

3.2. Systemic Lupus Erythematosus. CVD is at least doubled among SLE patients compared to other populations and mortality is also increased [27]. CVD burden in SLE includes carotid plaques, MI, angina, CHF, stroke, IMT, PVD, pericarditis, and others discussed below [16, 28–35]. Table 2 shows traditional and nontraditional risk factors associated with CVD in SLE.

3.3. Antiphospholipid Syndrome. The prevalence of CVD ranges from 1.7 to 6%, and it could increase up to 14% in patients with antiphospholipid antibodies (APLA). On the other hand, the prevalence of CVD in asymptomatic AT reaches 15% compared to 9% in SLE patients and 3% in normal controls [36, 37]. In the Euro-Phospholipid cohort, MI was the presenting manifestation in 2.8% of the patients, and it appeared during the evolution of the disease in 5.5% of the cohort [38]. Cardiac manifestations may be found in up to 40%, but significant morbidity appears in only 4–6% of these patients. Most of these manifestations are explicable on the basis of thrombotic lesions either in the coronary circulation or on the valves [39]. Table 3 shows the main traditional and nontraditional risk factors associated with CVD in APS.

3.4. Sjögren’s Syndrome. CV events occurred in 5–77% with stroke, MI, CVA, DVT, and arrhythmias [40–44] being the most frequent. Furthermore, tricuspid regurgitation, injured mitral and aortic valves, pulmonary hypertension, and increased left ventricular mass have also been reported.
### Table 1: Traditional and nontraditional risk factors associated with CVD and RA.

| Risk factor                | Comments                                                                                                                                                                                                 | References            |
|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| **Traditional risk factors** |                                                                                                                                                                                                       |                       |
| Obesity                    | (i) Insulin resistance due to release of inflammatory cytokines such as TNF-α. (ii) Increased coronary calcification due to insulin resistance. (iii) ↑ Abdominal fat.                                            | [14, 233, 234]        |
| Dyslipidemia               | (i) ↓ HDL and ↑ LDL and TAG. (ii) Induces higher risk of IHD. (i) Old age prompts structural and functional deterioration in the heart and vessels structure.                                             | [14, 19, 97, 233–238] |
| Advanced age               | (ii) Senescent immune system is normally associated with phenotypical and functional changes.                                                                                                        | [233, 239]            |
| Family history of CVD     | Heritable factors: HTN and familial hypercholesterolemia. (i) Coexistence of T2DM and RA increases three times the risk of developing CVD. (ii) Abdominal obesity, antihypertensive medication, disease activity, and use of GCs affect glucose metabolism in RA patients. | [97, 240, 241]        |
| T2DM                       | (i) It is considered as biomarker for AT and a risk factor related to CAD and CVA.                                                                                                                                              | [14, 242, 243]        |
| Hyperhomocysteinemia       | (ii) There is still controversy about whether hyperhomocysteinemia is a causative agent of cardiovascular damage or only an epiphenomenon of inflammation. (iii) A high prevalence of this biomarker had a statistical association with male gender and higher radiological damage. | [235, 236, 244–248]  |
| Metabolic syndrome        | (ii) It was related to pain and functional status, suggesting disease activity (iii) Increased prevalence of waist circumference, blood pressure, and fasting glucose (i.e., worse prognosis). (iv) Increased epicardial adipose tissue volume. | [103, 236, 242, 247, 249–252] |
| Sedentary lifestyle        | (i) Patients are less physically active than controls due to pain, stiffness, deformity, and impaired mobility. (ii) Impairment of altered lipid pattern.                                                                 | [97, 252, 253]        |
| Hypertension               | Increases the risk of IHD and CVA with important impact on mortality.                                                                                                                                               | [249, 254, 255]       |
| Male gender                | Cardiovascular disease is more frequent in male gender.                                                                                                                                                           | [14, 254, 256–260]   |
| Smoking                    | (i) Smokers with RA have worse prognosis than nonsmokers RA patients in terms of RF titers, disability, radiological damage, CVD, and treatment response. (ii) Premature CVD mortality.                                                                 | [249, 261, 262]       |
| **Nontraditional risk factors** |                                                                                                                                                                                                       |                       |
| HLA-DRB1 SE                | (i) Its alleles are related to chronic inflammation, high disease activity, EAMs, endothelial dysfunction, increasing CV events, AT plaque, and premature mortality. Some of them are independent of autoantibody status. (ii) Being a carrier of a single copy of HLA-DRB1 SE was significantly associated with an increased risk of atherosclerotic plaque in RA Colombian patients. | [97, 145, 262–268]   |
| Genetic                    | (i) Polymorphisms in *endothelin-1, MTH-FR, TRAF1/C5, STAT4, factor XIlla, PAI-1, TNFR-II, LT-A, LGALS2, TGF-β, GSTT1, ACPI, and NF-κβ1* genes may be contributed to CVD risk and adverse outcome. (ii) Interaction between smoking and polymorphism in the *VEGFA* gene is associated with IHD and MI in RA patients. (iii) The *HL6-174* gene polymorphism may play a role in the development of subclinical atherosclerosis in patients with RA. (iv) *TNFA rs1800629 (G>A)* gene polymorphism is associated with predisposition to CV complications in RA patients. This predisposition seems to be restricted to individuals carrying the SE. (v) Genetically determined high serum levels of MBL and high serum levels of agalactosyl IgG are associated with increased risk of IHD, MI, and premature death. | [78, 97, 269–286]     |
| Risk factor                        | Comments                                                                 | References                          |
|-----------------------------------|--------------------------------------------------------------------------|-------------------------------------|
| RA per se                         | (i) Independent factor for developing MI and accelerated AT.             | [14, 19, 287]                       |
|                                   | (ii) It represents a broad spectrum of conditions related with the autoimmune nature of the disease. |                                     |
| Familial autoimmunity             | (i) It confers additional susceptibility to CVD in RA patients, as well as presence of atherosclerotic plaque, radiographic progression, high disease activity, and persistent inflammation. | [14, 97]                            |
|                                   | (ii) Increased frequency of HLA-DR4.                                     |                                     |
|                                   | (i) It targets inflammation but its adverse effects include carotid plaques, arterial stiffness, decreased insulin sensitivity, elevated lipid levels, hypertension, and CVD. | [14, 19, 111, 124, 240, 288–294]    |
| Glucocorticoids                   | (i) Patients that are treated with a daily dose >7.5 mg/day appeared to have twice as the risk of heart disease as patients that are in nonsteroidal treatment. | [14, 19, 111, 124, 240, 288–294]    |
|                                   | (ii) The increased mortality in patients under low-dose oral GC for more than 10 years has been related mainly to CVD. | [14, 19, 111, 124, 240, 288–294]    |
|                                   | (i) Disease duration over 10 years was significantly associated with increased risk of atherosclerotic plaque in Colombian population. | [97, 102, 240, 290, 295–298]        |
| Long duration of disease          | (ii) Patients with prolonged RA have more atherosclerosis than patients of the same age with more recent disease onset. They have more extensive subclinical atherosclerosis or CAC, independent of other CHD risk factors. | [97, 102, 240, 290, 295–298]        |
|                                   | (iii) RA duration is independently associated with LVDD suggesting the impact of chronic autoimmune inflammation on myocardial function. | [97, 102, 240, 290, 295–298]        |
| Polyautoimmunity                  | It was associated with CVD in Colombian population.                     | [299]                               |
| RA-associated Autoantibodies      | (i) Immune complexes from RF can be deposited in the endothelium generating endothelial dysfunction and AT through inflammatory reactions. | [9, 97, 238, 299–314]              |
|                                   | (ii) RF-positive patients were at increased risk of CV events following exposure to GC. | [9, 97, 238, 299–314]              |
|                                   | (iii) RF titers were independently predictive of endothelial dysfunction and increased mortality in RA. | [9, 97, 238, 299–314]              |
|                                   | (iv) Anti-CCP and RF-IgM were related to impaired endothelial function independent of other CV risk factors, and they are independently associated with impaired left ventricular relaxation and development of IHD. | [9, 97, 238, 299–314]              |
|                                   | (v) Anti-ox-LDL, ACLA, APLA, and anti-ApoA-1 are associated with early atherosclerotic changes and future thrombotic events. | [9, 97, 238, 299–314]              |
|                                   | (vi) The presence of ACLA and an altered lipid profile may represent an important risk factor for thrombotic events in patients affected by RA. Anti-PC, anti-HSP 60/65, and anti-MDA-LDL may have independent roles in subclinical AT. | [9, 97, 238, 299–314]              |
|                                   | (vii) Anti-ox-LDL was strongly related with the degree of inflammation and carotid plaque and may predispose to a higher risk for CVD, as they were independently associated with subclinical atherosclerosis. | [9, 97, 238, 299–314]              |
|                                   | (viii) High levels of anti-MCV and LDL-immune complexes are risk factors for increased AT and are associated with inflammation. | [9, 97, 238, 299–314]              |
|                                   | (i) It may accelerate atherogenic processes and microvascular dysfunction: accentuation of known pathways of plaque formation. | [9, 97, 238, 299–314]              |
|                                   | (ii) Inflammatory stimuli may be involved in the initiation of CHF among patients with RA. | [9, 97, 238, 299–314]              |
| Chronic proinflammatory state     | (iii) Markers of chronic inflammation (i.e., current and cumulative inflammation) such as CRP, ESR, TNF-α, IL-6, IL-17, and haptoglobin are present in endothelial activation and increased in carotid IMT, carotid plaque, CAD, CV complications, and mortality. | [8, 24, 73, 75, 99, 260, 300, 315–319] |
|                                   | (iv) Both established CV risk factors and manifestations of RA inflammation contribute significantly to carotid atherosclerosis in RA and may modify one another's effects. | [8, 24, 73, 75, 99, 260, 300, 315–319] |
| High disease activity             | (i) Higher activity index is associated with CV events and mortality.    | [97, 268, 300, 316, 320, 321]       |
|                                   | (ii) DAS-28 was a significant predictor of major adverse CV events and mortality. | [97, 268, 300, 316, 320, 321]       |
|                                   | (iii) The occurrence of new CV events in very early RA was explained by traditional CV risk factors and was potentiated by high disease activity. | [97, 268, 300, 316, 320, 321]       |
carotidstenosis, compared to 35% of the control patients [55]. Doppler results have shown that 64% of the patients have and myocardial fibrosis [46, 52, 54, 56–60] are also defined. Arrhythmias, coronary spasm, MI, PVD, CVA, CAD, LVDD, light polypeptide gene enhancer in B-cells 1; NO: nitric oxide; OPG: osteoprotegerin; OPN: osteopontin; PAI-1: plasminogen activator inhibitor type-1; IL6: interleukin 6; activator inhibitor type-1; RA: rheumatoid arthritis; RF: rheumatoid factor; SE: shared epitope; sPTX-3: serum pentraxin-3; STAT4: signal transducer and activator of transcription 4; T2DM: type 2 diabetes mellitus; TAG: triglycerides; TGF-β1: transforming growth factor beta; TNF-α: tumor necrosis factor-α; TNFRII: tumor necrosis factor receptor II; TRAFI/CS: TNF receptor-associated factor I; VEGF-A: vascular endothelial growth factor A.

| Risk factor | Comments | References |
|-------------|----------|------------|
| EAMs        | (i) Increases three times the risk of having CVD and these patients, also present greater IMT. (ii) CVD is considered a severe EAM of the disease. (iii) Severe EAM manifestations are associated with an increased risk of CVD events. Systemic EAM disease is a major determinant of CVD morbidity. | [145, 240, 266, 296, 322–324] |
| Household duties | Employed women are somewhat less physically disabled than their unemployed counterpart (including housework). | [14, 325, 326] |
| Hypothyroidism | Fourfold higher risk of CVD even after adjustment for other traditional CV risk factors. | [241, 327, 328] |
| Thrombogenic and other factors | (i) State of hypofibrinolysis is associated with CVD progression and levels of von Willebrand factor, PAI-1, and tissue type plasminogen | [254, 289, 297, 311, 329–341] |
| Rheumatoid cachexia | Associated with high levels of LDL, low levels of atheroprotective anti-PC, and high frequency of HTN in RA patients. | [24, 336, 342, 343] |

3.5. Systemic Sclerosis. A broad spectrum of subphenotypes and mortality due to CVD have been described. Mortality in patients with SSc caused by CVD is between 20 and 30% and, despite being similar to the general population, it occurs a decade earlier [II]. CV symptoms are found in 10% of the SSc patients while asymptomatic patients with coronary artery calcification (CAC) accounted for approximately 33.3% in diffuse SSc and 40% in limited SSc [46–54]. However, Doppler results have shown that 64% of the patients have carotid stenosis, compared to 35% of the control patients [55]. Arrhythmias, coronary spasm, MI, PVD, CVA, CAD, LVDD, and myocardial fibrosis [46, 52, 54, 56–60] are also defined. Table 5 shows the main traditional and nontraditional risk factors associated with CVD in SSc.

4. Discussion

This review adds further evidence about high frequency of CVD in patients with ADs and their traditional (i.e., dyslipidemia, abnormal BMI, and male) and nontraditional risk factors (i.e., steroids, household duties, and autoantibodies) [14, 15]. It also highlights the impact on public health and the need to develop new strategies in prediction, prevention, and treatment. Through the review, several factors and outcomes related to CVD were also identified.

4.1. Physiopathology of Atherosclerosis in AD. AT is a multifactorial, chronic, and inflammatory disease that had been traditionally viewed as a lipid-based disorder affecting the vessel walls. Nowadays, this theory has been modified, and it is known that all arms of the immune system take part in atheroma formation. The increased understanding of the mechanisms promoting vascular damage has recently led to a sharper focus on proinflammatory pathways, which appear to play a key role in the development and propagation of the disease. Thus, some of the mechanisms that drive atherosclerotic plaque formation, and therefore CVD, are shared with several ADs although each disease may have particular immunological aberrations that provide specific proatherogenic pathways [5–7, 16, 24, 61–68]. This process is characterized by the accumulation of lipid particles, immune cells, autoantibodies, autoantigens, and the multiple production of inflammatory cytokines such as tumor necrosis factor-α (e.g., TNF-α). All these components lead to a gradual thickening of the intima layer, thus causing a decrease in elasticity, narrowing of the arterial lumen, reduction of blood flow, plaque rupture, and, finally, the CV event [69, 70]. The systemic inflammatory response that characterizes AT also involves acute-phase reactants such as erythrocyte
### Table 2: Traditional and nontraditional risk factors associated with CVD and SLE.

| Risk factor       | Comments                                                                                                                                                                                                 | References |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| **Traditional risk factors**                                                                                                                                  |                                                       | [32, 152, 344–360] |
| **Hypertension** | (i) It is more frequent among SLE patients than people with noninflammatory disorders  
(ii) It acts as CVD subphenotype as well as a risk factor and also influences the risk of death by CVD. It increases the risk of thrombosis and it is more prevalent among SLE patients with atherosclerotic plaque.  
(iii) Lupus patients with abnormal myocardial scintigraphic findings and hypertension, as risk factor for CAD, had a higher risk of abnormal findings on coronary angiography.  
(i) T2DM has influence on abnormal myocardial perfusion in asymptomatic patients with SLE.  
(ii) Alterations in glycemic profile were associated with traditional risk factors for CHD and lupus characteristics, including CVD, damage index, and renal involvement.  
(iii) Patients with SLE and T2DM were at increased risk of thrombosis, atherosclerotic plaque, and CAC. This risk remains elevated throughout the course of the disease.  
(i) The main risk factor for death in SLE was heart involvement, which was influenced by dyslipidemia. The inflammatory context of SLE leads to dysregulation of lipid metabolism pathways → increased risk of atherosclerotic disease and thrombotic events.  
(ii) Alterations in lipid profile were a risk factor for endothelial dysfunction, myocardial perfusion abnormalities, and premature CAC and CAD in young women.  
(i) Male gender was a risk factor for developing severe organ damage (CVD) and mortality in SLE patients.  
(ii) Males with SLE were at increased risk of thrombosis and CAC. This risk remains elevated throughout the course of the disease.  
(iii) Patients had more peripheral vascular and gonadal involvement.  
(i) SLE patients had a high prevalence of MetS that directly contributes to increasing inflammatory status and oxidative stress.  
(ii) MetS were associated with traditional risk factors for CAD and lupus characteristics, including CVD, damage Index, and renal involvement.  
(iii) HCQ use proved to be protective against MetS.  
(iv) Insulin sensitivity and intima-media thickness are altered in SLE patients, especially those with MetS comorbidity with an associated increase in disease activity and damage  
(v) Renal lupus, higher corticosteroid doses, Korean and Hispanic ethnicity are associated with MetS in SLE patients.  
(i) Patients with SLE who had excess weight present distinct clinical-laboratory findings, sociodemographic characteristics, and treatment options when compared to normal weight patients. Excess weight is associated with SLE poor prognosis.  
(ii) Increased weight has influence on abnormal myocardial perfusion in asymptomatic SLE patients.  
(iii) SLE patients with high BMI have increased QT interval parameters, presence of CAD, and carotid plaque. This prolongation may lead to an increased CV risk.  
(i) Smoking is an important determinant in the occurrence of thrombotic (central and/or peripheral, arterial and/or venous) events in SLE patients, due to atherosclerotic plaque and thrombosis  
(ii) Smoking habits influence abnormal myocardial perfusion in asymptomatic SLE patients.  
(iii) Smoking was a risk factor for premature CAC and CAD in young women with SLE. | [32, 252, 349–352, 354, 356, 357, 363–369] |
| **T2DM**         |                                                                                                                                            | [32, 252, 349–352, 354, 356, 357, 361, 362] |
| **Dyslipidemia** | (i) |                                                                                                                                            | [252, 344, 345, 350–352, 354, 356, 357, 363–369] |
| **Metabolic syndrome** | (i) |                                                                                                                                            | [252, 358, 359, 372–377] |
| **Male gender**  | (i) |                                                                                                                                            | [32, 350, 351, 357, 361, 367, 370, 371] |
| **Obesity**      | (i) |                                                                                                                                            | [32, 252, 345, 349, 352, 357, 358, 369, 378–380] |
| **Smoking**      | (i) |                                                                                                                                            | [252, 345, 350–352, 354, 357, 358, 370, 372, 381, 382] |
| Risk factor | Comments | References |
|------------|----------|------------|
| Advanced age | Several traditional risk factors, including age, appear to be important contributors to atherosclerotic CV damage. (i) High percentage of SLE patients with abnormal angiographic findings was in postmenopausal status. (ii) There is high prevalence of premature menopausal status as risk factor for CVD. (iii) Postmenopausal status was a risk factor for premature CAC in young women with SLE. (iv) Postmenopausal women had a higher prevalence of subclinical AT and abnormal myocardial perfusion in asymptomatic patients with SLE. | [349, 352, 361, 383, 384] |
| Menopausal status | (i) Familial history of CVD was an independent risk factor for atherosclerotic process and premature CAC in women with SLE. (ii) Family history of CVD influences abnormal myocardial perfusion in asymptomatic SLE. | [32, 351, 352, 354, 357, 358] |
| Family history of CVD | HRT use was not associated with the occurrence of vascular arterial events in the LUMINA patients. HRT use in women with SLE should be individualized, but data suggest its use may be safe if APLA are not present or vascular arterial events have not previously occurred. | [32] |
| Hyperhomocysteinemia | (i) Hyperhomocysteinemia was a risk factor for CAC in SLE patients. (ii) The presence of polyautoimmunity and hyperhomocysteinemia was a risk factor for thrombotic events. | [351, 387] |
| Nontraditional risk factors | | |
| Ancestry | There are several differences regarding clinical (including CVD), prognostic, socioeconomic, educational, and access to medical care features in GLADEL cohort according to ancestry (White, Mestizo, and African-LA). | [15, 360, 388] |
| Genetic determinants | (i) A SNP in FGG rs2066865 demonstrated association with arterial thrombosis risk in Hispanic American patients with SLE. (ii) The CRP GT20 variant is more likely to occur in African-American and Hispanic SLE patients than in Caucasian ones, and SLE patients carrying the GT20 allele are more likely to develop vascular arterial events (LUMINA multietnic cohort). (iii) TRAF3IP2 may affect disease phenotype and, particularly, the occurrence of pericarditis. (iv) There is a considerable genetic component for CAD with IRF8 as a strong susceptibility locus. | [382, 389–391] |
| Non-HLA | (i) The presence of APS and its characteristic antibodies was the major independent contributor to the development of thrombotic events and severe organ damage. (ii) Polyautoimmunity (e.g., APS) may suggest concerted pathogenic actions with other autoantibodies in the development of thrombotic events. (i) SLE diagnosis is associated with carotid plaque formation and development of CV event. (ii) High percentage of patients with abnormal angiographic findings had higher ACR criteria number for SLE. (iii) Endothelial dysfunction is associated with traditional and SLE-specific risk factors, and early data suggest reversibility of endothelial dysfunction with therapy. | [3, 15, 353, 392–394] |
| Polyautoimmunity | (i) One of the independent predictors of vascular events in a multiethnic US cohort (LUMINA) was the presence of any APLA. (ii) Anti-β2GPI antibodies were strongly associated with thrombosis. The decrease of anti-β2GPI levels at the time of thrombosis may indicate a pathogenic role. | [32, 365, 371, 392, 395–398] |
Table 2: Continued.

| Risk factor                | Comments                                                                                                                                                                                                 | References |
|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| (iii)                      | The higher frequency of aPT found in thrombosis may suggest concerted pathogenic actions with other autoantibodies in the development of thrombotic events.                                             |            |
| (iv)                       | Patients with ACLA seem to be at an increased risk for arterial and venous thrombotic events and showed an association with echocardiographic abnormalities.                                             |            |
| (v)                       | There was correlation between lupus anticoagulant and thrombotic events in Brazilian lupus patients.                                                                                                      |            |
| (i)                       | Complement fixing activity of ACLA seems to be relevant in thrombotic venous events.                                                                                                                   | [393, 399] |
| Immune cells aberrations  | (ii) Activation of endothelial MMP-2 by MMP-9 contained in NETs as an important player in endothelial dysfunction and MMP-9 as a novel self-antigen in SLE. These results further support that aberrant NET formation plays pathogenic roles in SLE. |            |
| Inflammatory markers       | (i) Increased ESR and CRP were independently associated with MetS and vascular events in lupus patients.                                                                                                   | [32, 361, 373] |
| (i)                       | HDL distribution and composition (+HDL2b, +HDL3b, and +HDL3c) were abnormal in SLE patients.                                                                                                             | [400–402]  |
| (ii)                      | Low HDL levels and increased TAG levels were associated with AT by cIMT measurement.                                                                                                                                 |            |
| (iii)                     | SLE pattern of dyslipoproteinemia may increase the risk of developing CAD.                                                                                                                                |            |
| Endogenous dyslipidemia   | (i) Disease activity (SLAM) is an important determinant in the occurrence of thrombotic (central and/or peripheral, arterial and/or venous) events in the LUMINA cohort.                                      |            |
| SLE-associated Disease activity | (ii) SLEDAI scores were positively correlated with abnormal BMI and WC.                                                                                                                                       |            |
| (iii)                     | Higher disease activity (i.e., SLEDAI and SLICC) is a predictor of CAC and it was independently associated with MetS, myocardial perfusion abnormalities, and thrombosis. Higher score of SDI was associated with atherosclerotic plaque in Brazilian SLE patients. | [350, 351, 356, 369, 372, 373, 381, 402–404] |
| Organ damage              | (iii) MetS was associated both with traditional risk factors for CHD and with lupus characteristics including damage index.                                                                                 | [358, 361, 369, 371, 405, 406] |
| Long duration             | (iv) There was a correlation between IMT and revised damage index (SLICC).                                                                                                                                |            |
| Medications               | (v) Atherosclerotic CV damage in SLE is multifactorial, and disease-related factors (including CRP levels and SDI at baseline) appear to be important contributors to such an occurrence.                            |            |
| (i)                       | Acorrelation between IMT and duration of the disease was found in SLE patients.                                                                                                                            | [352, 354, 369, 383] |
| Long duration             | (ii) Disease duration was an independent predictor for premature CAC in young women with SLE.                                                                                                              |            |
| Medications               | (i) PDN >10 mg/day was independently associated with MetS and IMT in SLE patients.                                                                                                                         | [352, 355, 373] |
| (ii)                      | IHD was observed in SLE patients: those with long term steroid therapy and those with frank episodes of vasculitis.                                                                                       |            |
Furthermore, activated smooth muscle cell migration, proliferation, and foam cell formation, in combination, activates T cells even more and favors production of TNF-α. This kind of reaction is greater in several ADs with a high density of T cells, predominantly lymphocyte T helper 1 (Th1), which enhances a cascade of Mφ activation and release of pro-inflammatory cytokines (e.g., IL-2, IL-6, IL-17, and so forth), which can present antigens to T cells such as ox-LDL and heat shock proteins (HSP) 60/65 [4, 61]. The immune regulatory molecule CD40 ligand and its receptor CD40 are expressed by Mφ, T cells, endothelium, and smooth muscle. Both are upregulated in lesions of AT and thus provide further evidence of immune activation [5, 86]. As ox-LDL is a macromolecule with many potential autoantigens, it is possible that anti-oxidized low-density lipoprotein antibodies (anti-ox-LDL) represent a family of autoantibodies against different autoantigens involved in CVD. Thus, the clinical impact of these autoantibodies might vary. However, there are reports showing that elevated anti-ox-LDL titers have been detected in patients with early-onset PVD, severe carotid AT, CHF, CAD, MI, and death [87, 88]. This suggests a proatherogenic role for these autoantibodies and supports a key role for them in the progression of AT [87, 89, 90].

Beta-2 glycoprotein-1 (β2GPI) is considered to be an autoantigen in APS. Moreover, it is abundantly expressed within the subendothelial regions and in the intima-media layers at the border of atherosclerotic plaque. Both IgM and IgG anti-β2GPI levels are elevated in patients with AT and other inflammatory conditions [91]. β2GPI is the actual autoantigen for most anticardiolipin antibodies (ACLA), a group of antibodies with procoagulant activity. The association between APLA, AT, and thrombosis can also be seen outside the setting of autoimmunity. Thus, ACLA promote AT by attracting monocytes into the vessel wall and inducing monocyte adherence to endothelial cells. All of this is mediated by adhesion molecules such as ICAM-1, VCAM-1, and E-selectin [7, 92]. The APLA should be considered more than an AT marker since they can enhance AT and are proatherogenic.
Table 3: Traditional and nontraditional risk factors associated with CVD and APS.

| Risk factor            | Comment                                                                 | Reference          |
|------------------------|-------------------------------------------------------------------------|--------------------|
| **Traditional risk factors** |                                                                        |                    |
| Metabolic syndrome    | The most common risk factors are hypertriglyceridemia, low HDL levels, and visceral obesity. | [409, 410]         |
| Hyperlipidemia         | High levels of APLA may be a marker for earlier endothelial damage caused by hyperlipidaemia. | [410, 411]         |
| T2DM                   | It is associated with cardiovascular disease among APS patients. It did not show any difference between APS patients and the general population. | [410, 412]         |
| Smoking                | CVD risk factor increases risk of AT.                                    | [410, 412]         |
| Obesity                | Increases the risk of insulin resistance and MetS.                       | [410, 412]         |
| HTN                    | Increases risk of ischemic events and CVD.                               | [410, 412]         |
| Sedentary lifestyle    | Increases risk of obesity and comorbidities, propending CVD.             | [410, 412]         |
| **Nontraditional risk factors** |                                                                   |                    |
| APS per se             | Patients with primary APS have a high prevalence of carotid IMT and a decreased lumen diameter. IMT in primary APS may be associated with stroke. Patients with primary APS with IMT must be considered as carriers of atherosclerosis. | [204]              |
| Autoantibodies         | (i) ACLA are associated with a higher risk of venous thrombosis and arterial thrombosis. | [145, 186, 204, 413–419] |
|                        | (ii) Lupus anticoagulant is a major risk factor for arterial thrombotic events. |                    |
|                        | (iii) Immunoinflammatory mechanisms, primarily APLA, have an outstanding role in APS-related vasculopathies. |                    |
|                        | (iv) Patients having APLA and AT may have greater risk for ischemic events than patients with the same degree of AT but without APLA. |                    |
|                        | (v) β2GPI is abundantly present in the atherosclerotic plaque. |                    |
|                        | (vi) Anti-β2GPI and ACLA may be involved in CAD and stroke. |                    |
|                        | (vii) CAD and PVD occurred more often in patients with elevated serum levels of IgG or IgM APLA, including ACLA or anti-β2GPI. |                    |

ACLA: anticardiolipins antibodies; anti-β2GPI: anti-β2 glycoprotein I antibodies; APLA: antiphospholipid antibodies; APS: antiphospholipid syndrome; AT: atherosclerosis; β2GPI: β2 glycoprotein I; CAD: coronary artery disease; CVD: cardiovascular disease; HDL: high-density lipoprotein; HTN: hypertension; IMT: intima-media thickness; MetS: metabolic syndrome; PVD: peripheral vascular disease; T2DM: type 2 diabetes mellitus.

Likewise, serum from patients with CVD shows a high prevalence of antibodies against HSP60, which mediate lysis of stressed endothelial cells [91, 95, 96].

4.2. Rheumatoid Arthritis. In addition to diarthrodial joints, RA can damage virtually any organ thus leading to potential extra-articular manifestations (EAMs). CVD is considered an EAM and represents the major predictor of poor prognosis and the main cause of death in this population [13, 17, 97, 98]. There is evidence that vascular damage accrual begins prior to the diagnosis of RA and accelerates as the disease progresses. RA patients present with endothelial dysfunction and increased subclinical AT compared to age-matched controls [99–101]. Endothelial function, assessed by brachial artery flow-mediated vasodilation, also worsens with disease duration [102]. The CV mortality is higher in RA and life expectancy of patients with RA is three to ten years less than that of the general population [103, 104]. CVD is known to appear earlier and 3.6 times more frequently than in the general population [70, 98, 105]. Thus, CVD is the leading cause of death for RA patients around the world [106, 107]. Currently, IHD secondary to AT is the most prevalent cause of death associated with CVD in RA patients [108]. Almost all mortality studies have been done on populations of European origin, and there is limited information on other ethnic groups. A meta-analysis of 24 RA mortality studies, published between 1970 and 2005, reported a weighted combined all-cause standardized mortality ratio (meta-SMR) of 1.50 with similar increases in mortality risk apparent from the ratios for IHD (meta-SMR 1.59) and for CVA (meta-SMR 1.52).
Table 4: Traditional and nontraditional risk factors associated with CVD and SS.

| Risk factor        | Comment                                                                 | Reference                  |
|--------------------|-------------------------------------------------------------------------|----------------------------|
| Dyslipidemia       | (i) High prevalence of hyperlipidemia and low HDL are associated with CVD and first-degree heart block. (ii) SS patients showed 1.5-fold higher prevalence of hypertriglyceridemia. | [12, 42–44, 210, 420]      |
| T2DM               | It is associated with CV compromise in SS patients.                      | [210]                      |
| Advanced age       | Age is a predictor for valve compromise                                  | [45]                       |
|                    | **Nontraditional risk factors**                                         |                            |
| Systemic compromise| Articular, renal, peripheral neuropathy, CNS, joint and gastrointestinal involvement, and parotid enlargement are associated with stroke, IHD and lower flow-mediated vasodilation | [12, 42, 210]              |
| Polyautoimmunity   | SS patients with APS were significantly associated with APLA in thrombotic events. (i) SS-A is associated with stroke, IHD, and carotid thickening. (ii) SS-B is related to first-degree heart block, valve compromise, and lower nitrate mediated vasodilation. (iv) ACLA IgG is associated with arrhythmias (v) RF is related to lower nitrate mediated vasodilation. (vi) Anti-HDL. | [12, 41–43, 210, 211, 420] |
| SS-associated Autoantibodies | (iii) APLA and lupus anticoagulant are associated with thrombotic events. (iv) ACLA IgG is associated with stroke, IHD; (v) RF is related to lower nitrate mediated vasodilation. (vi) Anti-HDL. | [12, 41–43, 210, 211, 420] |
| Long duration of disease | Longer duration of the disease is associated with stroke and IHD. | [210, 420]                |
| Chronic proinflammatory state | Elevated CRP is associated with stroke and IHD | [43, 210]                  |
| Glucocorticoids    | (i) Steroid use is associated with stroke and IHD (ii) Patients with GCs showed a higher frequency of HTN, T2DM, and elevated TAG. | [42, 210]                  |
| Others             | (i) Hypogammaglobulinemia, leukopenia, thrombocytopenia, and s-VCAM-1 are associated with thrombotic events and lower nitrate mediated vasodilation. (ii) Low C4 and cryoglobulinemia are predictors for valve injury | [12, 42, 45, 210, 211, 420] |

ACLA: antiphospholipid antibodies; anti-HDL: anti-high-density lipoprotein antibodies; APLA: antiphospholipid antibodies; APS: antiphospholipid syndrome; CNS: central nervous system; CRP: C-reactive protein; CV: cardiovascular; CVD: cardiovascular disease; GCs: glucocorticoids; HDL: high-density lipoprotein cholesterol; HTN: hypertension; IHD: ischemic heart disease; RF: rheumatoid factor; SS-A: anti-Ro/SSA antibodies; SS-B: anti-La/SSB antibodies; SS: Sjögren’s syndrome; s-VCAM: soluble vascular cell adhesion molecules; TAG: triglycerides; T2DM: type 2 diabetes mellitus.

[109] RA patients with CVD frequently experience “silent” IHD with no symptoms before a sudden cardiac death. Indeed, sudden cardiac deaths are almost twice as common in patients with RA as in the general population [110]. According to the above, the Rochester Epidemiology Project [100] showed that patients with RA had a greater risk of MI than controls of equivalent age and sex. Recently, Sarmiento-Monroy et al. [13] did a systematic literature review of CVD in the Latin American (LA) population. A wide range of prevalence for CVD has been reported (13.8–80.6%) for this population. The highest prevalence was indicated in Puerto Rican patients (55.9%) by Santiago-Casas et al. [111], while for Brazil [112, 113], Colombia [14, 97, 114, 115], and Argentina [116, 117], a similar prevalence was reported (47.4, 35.1, and 30.5%, resp.). However, the mortality in RA patients has been poorly evaluated in this population. Acosta et al. [118] demonstrated a mortality rate of 5.2% in a six-year follow-up. For both, the most frequent cause of death was CVD in 44.7% and 22.2% of the cases, respectively. Table 1 and Figure 1 give a summary of the main findings related to traditional and nontraditional CVD risk factors in RA patients. In the Colombian population, Amaya-Amaya et al. [14] found that the traditional risk factors including male gender, hypercholesterolemia, and an abnormal body mass index (BMI) were associated with CVD. Nevertheless, the increased prevalence of CV events in RA is not fully explained...
Table 5: Traditional and nontraditional risk factors associated with CVD and SSc.

| Risk factor        | Comments                                                                                          | References |
|--------------------|---------------------------------------------------------------------------------------------------|------------|
| **Traditional risk factors**                                                                 |                                                      |            |
| Dyslipidemia       | (i) The alteration of lipid profile has been described, given by the increased levels of LDL and lipoprotein A, which are related to the reduction in the fibrinolysis and thrombotic and coronary events.  
(ii) Decreased levels of HDL are related to anticentromere antibodies positivity.  
(iii) There is elevation of TAG, total cholesterol, and LDL and decrease in HDL levels. | [214, 218, 421–424] |
| T2DM               | It is associated with CV events in SSc patients.                                                   | [54, 424]  |
| Hypertension       | Its prevalence increased with the age, and it is correlated with MI.                              | [54]       |
| Hyperhomocysteinemia | Increased levels are related to AT and endothelial dysfunction.                                   | [218]      |
| **Nontraditional risk factors**                                                                                      |            |
| SSc per se         | It is an independent risk factor for MI                                                          | [54]       |
| Autoantibodies     | (i) oxLDL/β2GPI and anti-oxLDL/β2GPI complex: these are considered proatherogenic.  
(ii) anti-ox-LDL: higher levels are correlated with AT and thrombosis.  
(iii) anti-LPL: its presence is related to TAG elevated and AT and CV events.  
(iv) AECA may also contribute to an increased risk of early AT in SSc  
(v) Others: anticentromere, anti-HSP65/60, and APLA. Increase of CRP levels and intercellular adhesion molecule-1 may also contribute to an increased risk of early AT in SSc. | [91, 220, 423, 425–429] |
| Chronic inflammation| AECA: anti-endothelial cell antibodies; anti-HSP: anti-heat shock proteins antibodies; anti-LPL: anti-lipoprotein lipase antibodies; an anti-oxLDL/β2GPI complex; anti-oxidized low-density lipoprotein/β2 glycoprotein I antibodies; APLA: antiphospholipid antibodies; AT: atherosclerosis; CRP: c-reactive protein; CV: cardiovascular; CVD: cardiovascular disease; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein; oxLDL/β2GPI complex: oxidized low-density lipoprotein/β2 glycoprotein I; SSc: systemic sclerosis; TAG: triglycerides; T2DM: type 2 diabetes mellitus. |            |

by these classic risk factors. Both nontraditional RA risk factors and traditional risk factors act together to develop CVD (Figure 1).

Regarding CV risk screening and management, strategies have been developed for the general population and are based on CV risk score calculators such as the Framingham score and the Systematic Coronary Risk Evaluation (SCORE) model, but the accuracy of these models has not been adequately evaluated in inflammatory arthritis [119]. Recent studies have shown that the SCORE underestimates the actual cardiovascular risk of patients with RA. In this regard, a study showed a high frequency of carotid plaques in the group of individuals included in the category of moderate risk according to SCORE risk charts [120]. The major strategy is to develop healthy life styles as a way to maintain control of classical risk factors. Statins can effectively lower total cholesterol in RA patients and significantly improve the rates of CV-related and all-cause mortality when used for primary prevention of vascular events [121, 122]. Similarly, ACE inhibitors and angiotensin II blockers may also have a favorable effect on inflammatory markers and endothelial function in RA [123, 124]. Regarding novel risk factors, it is necessary to establish an adequate management of the disease [19]. The main goal of the treatment should be to reduce the disease activity, and, therefore, decrease the CV burden [124]. Both conventional [125] and biological disease modifying antirheumatic drugs (DMARDs) are used for this purpose. Some studies have shown greater disease control with nonconventional DMARDs such as anti-TNF agents, which lower CRP and IL-6 levels, increase HDL levels, and improve endothelial function [126–129]. Effective treatment may also result in improved physical activity which subsequently leads to a decreased risk of hypertension, obesity, and diabetes, all important determinants of CV disease [127]. The antimalarial (AMS) drugs have been associated with a better CV outcome, enhanced glycemic control, improved lipid profiles, a decreased thrombosis risk, and a reduced probability of developing T2DM in patients with RA [127, 130, 131]. The glucocorticoids (GC) should be used prudently to minimize CV risk secondary to their effects on metabolic parameters and blood pressure. Altogether, there is no clear evidence that low doses of GC contribute significantly to an enhanced CV risk in inflammatory arthritis in contrast to high doses. GCs rapidly and effectively suppress inflammation in RA and their use might be justified for short-term treatment, for example, for “bridging therapy” in the period between initiation...
and response to DMARD treatment, although the debate does not appear to be settled yet. Therefore, a conservative approach was chosen in which the use of the lowest dose for the shortest period possible was recommended [19, 124, 125, 132]. Reports indicate that anti-TNF is independently associated with a lower CV risk due to the fact that it reduces CV events in young patients by improving the lipid profile, insulin resistance, endothelial function, and aortic compliance and decreasing progression rates of subclinical AT [124,133–138]. Other biological therapy also produces the same effect. A good example of that was the improvement of endothelial function following rituximab therapy in patients with RA that had been refractory to anti-TNF-alpha drugs [139, 140]. Finally, data about other biologics are conflicting and preliminary; as such, randomized, controlled studies are needed to identify their CV risk reduction role [69, 70].

4.3. Systemic Lupus Erythematosus. SLE occurs most often in young women of child-bearing age, the same population that is at the highest relative risk of subclinical AT [141, 142]. Classically, there is a bimodal mortality pattern among SLE patients with an early peak in the first 3 years after diagnosis due to active disease, infections, and nephritis and a second peak with deaths occurring 4–20 years after SLE diagnosis due to CVD as described by Urowitz et al. [143]. Although the overall mortality rate for SLE patients has improved over the past 30 years, mortality due to CVD (i.e., 3–25%) has remained the same [144–146]. There is strong epidemiologic evidence that CVD risk among SLE patients compared to the general population is at least doubled [27]. Carotid plaque is prevalent in 21% of SLE patients under age 35 and in up to 100% of those over age 65 [147]. The increased risk of MI and angina among SLE patients...
has been well characterized in a number of population-based studies [146, 148–152]. Bengtsson et al. [152] further corroborated these results in their population-based Swedish study where they demonstrated that the risk of CVA and/or MI in the total SLE population was 1.27-fold higher than in the general population, but among women with SLE aged 40–49, it was 8-fold higher over the 7-year follow-up period. Several research groups have reported prevalence rates in SLE cohorts. In the Systemic Lupus International Collaborating Clinics-Registry for Atherosclerosis (SLICC-RAS) cohort, there were 8 cases of PVD among 1,249 patients during a 2-year period [153]. In the Lupus in Minorities: Nature versus Nurture study (LUMINA), 5.3% of 637 patients developed PVD over a mean follow-up of 4.4 years [154]. In a recent meta-analysis, Schoenfeld et al. [27] showed that epidemiological data strongly support the hypothesis that SLE patients are at an elevated relative risk of CVD. The variability regarding the relative importance of risk factors for CVD among SLE patients in past epidemiological studies is likely due, in part, to different design methods and different patient and comparison groups. Independent predictive risk factors (from multivariate analysis) for CV events have been assessed in five large prospective cohorts of patients with SLE, including the Baltimore [155], Pittsburg [149], LUMINA [32], Toronto [156], and SLICC-RAS [153] cohorts. The main results are discussed in Table 2 and Figure 2. Diverse SLE cohorts have shown the influence of advanced age, dyslipidemia, obesity, HTN, and hyperhomocysteinemia as classical

Figure 2: Traditional and autoimmune-related mechanisms of cardiovascular disease in systemic lupus erythematosus and antiphospholipid syndrome. A complex interaction between traditional and disease-specific traits leads to premature atherosclerosis process. Several risk factors (left) have been described since the Framingham heart study, known as classic risk factors, which over time conducte to endothelial dysfunction, subclinical atherosclerosis, and CV event manifest. In the autoimmune setting (right), several novel risk factors contribute to development of premature vascular damage. This damage is represented by impaired endothelial function and early increase of intima-media thickness, which are surrogates of the accelerated atherosclerosis process. These associations are even more pronounced in this case of polyautoimmunity (SLE and APS in the same individual), where risk factors have additive effects and atherosclerosis develops earlier. The cornerstone of management of CV risk includes an aggressive treatment of disease activity, the continuous monitoring and treatment of modifiable CV risk factors, and the use of other medications in order to diminish the CV burden. ACE-I: angiotensin-converting enzyme inhibitors; AMs: antimalarials; APS: antiphospholipid syndrome; AT-II blockers: angiotensin II receptor blockers; Auto-Ab: autoantibodies; AZA: azathioprine; CIC: circulating immune complex; CYC: cyclophosphamide; CVD: cardiovascular disease; HDL: high-density lipoprotein; HRT: hormone replacement therapy; IECAs: angiotensin converting enzyme inhibitors; IR: insulin resistance; MetS: metabolic syndrome; MMF: mycophenolate mofetil; oxLDL/β2GPI complex: oxidized low-density lipoprotein/2 glycoprotein I; SLE: systemic lupus erythematosus; T2DM: type 2 diabetes mellitus.
risk factors for CVD in the lupus population [27, 157–159]. There is strong epidemiological evidence that traditional CVD risk factors also elevate CVD risk among SLE patients (Figure 2). Amaya-Amaya et al. [160] recently added further evidence of the high frequency of CVD in 310 consecutive patients with SLE (36.5%). Their findings on traditional risk factors (i.e., dyslipidemia, smoking), plus the confirmation that coffee consumption is another risk factor, showed that, in combination, they contribute to this complication in the LA population. It is well known that while traditional CVD risk factors are undoubtedly important in increasing the CVD risk among SLE patients, these do not fully account for the elevated risk of CVD in this population. Esdaile et al. [161] evaluated risk factors for CAD in two Canadian lupus cohorts by means of the Framingham multiple logistic regression model and found a high risk of developing CAD after removing the influence of these risk factors. Therefore, SLE-associated factors play an important role in the premature AT process characteristic of those patients [70,162–166].

Hence, there is an increasing interest in identifying novel risk factors that might explain the development of accelerated AT in these populations. The proposal has been made that SLE be managed the same way that T2DM is—as a “CVD equivalent”—with lower lipid goals, more aggressive aspirin use, and potentially more aggressive monitoring [167, 168].

Recent studies have started to address the question of whether traditional treatment regimens may prevent or slow AT in SLE patients [142]. There are several new mechanisms of action described for AMs, many of which have beneficial effects in the management of CV risk in patients with SLE [131, 169]. There is evidence that AM drugs reduce LDL levels, elevate HDL, and, when taken concomitantly with steroids, can reduce TC [170]. In addition, beneficial effects of HCQ on thrombosis formation have also been described [171–174]. Ruiz-Irastorza et al. [175, 176] found that HCQ use conferred a 50–60% decrease in the risk of CVD. Otherwise, the recent randomized controlled Lupus Atherosclerosis Prevention Study by Petri et al. [28] suggests that atorvastatin did not in fact slow progression of subclinical AT in 200 SLE patients over 2 years. However, in other studies, it has been demonstrated that statins do reduce CD40 levels in vivo and in vitro and, therefore, interfere with CD40-CD40 ligand interactions in both SLE and AT [177]. As inflammation is one of the targets of therapy in SLE, several other immunosuppressant drugs and biological therapies currently employed in SLE could also be considered such as potential new antiatherogenic agents [178, 179].

4.4. Antiphospholipid Syndrome. The APS is a prothrombotic state that can affect both the venous and arterial circulations. The deep veins of the lower limbs and cerebral arterial circulation are the most common sites of venous and arterial thrombosis, respectively [180]. The heterogeneity of APS clinical manifestations is likely linked to the varied effects that APLA can induce on endothelial cells [181]. Thrombotic events are the clinical hallmark of APS, occurring in venous and arterial circulations with a high recurrence rate of arterial involvement. They can be expressed as carotid disease, CVA, CAD, and PVD due to thrombus formation or AT [182–188]. Further, other cardiac manifestations may include irregular thickening of the valve leaflets due to deposition of immune complexes that may lead to vegetation and valve dysfunction, which are frequent and may be a significant risk factor for stroke [189–192]. Table 3 and Figure 2 show the main traditional and nontraditional risk factors associated with APS and CVD. Early diagnosis of APS through examination of the heart and aggressive control of all traditional risk factors through lifestyle modifications and pharmacotherapy, probably anti-inflammatory treatment, and close follow-up of APS patients may help to minimize CV risk in these individuals [189, 193]. The APS coagulopathy in these patients requires careful and judicious use of appropriate antiaggregant and anticoagulant therapy [39]. Specifically targeted therapies that exert anti-inflammatory or immunomodulatory effects become important therapeutic tools in APS. In order to achieve beneficial effects, these drugs should primarily antagonize the pathogenic effects of APLA. Moreover, these treatments should also control atheroma, which is one of the major causes of CV mortality in this pathology [177]. For instance, AM drugs may exert evident antiatherogenic properties [168, 194]. Statins also have pleiotropic characteristics, which include antiatherosclerotic (i.e., preventing endothelial dysfunction), anti-inflammatory (i.e., reducing CRP levels), antioxidant, immunomodulatory, and antithrombotic effects [195–200]. Likewise, aspirin has been used in primary and secondary prevention in APS patients particularly for its inhibitory effects on platelet aggregation [201, 202]. In addition to their anticoagulant effects, unfractionated heparins and low molecular weight heparins also have anti-inflammatory properties. Thus, heparins may represent another anti-inflammatory therapeutic tool even though the mechanisms of action responsible for their anti-inflammatory effects are not yet fully understood [203]. Recent improvements in the understanding of the pathogenic mechanisms have led to the identification of novel potential targets and therapies that might be used as new potential immunomodulatory approaches in APS and CVD such as B-cell targeted therapies, complement inhibition, inhibition of costimulation, intracellular pathway inhibition, and anticytokine therapies [204].

4.5. Sjögren’s Syndrome. This is an autoimmune epithelitis that affects the exocrine glands with a functional impairment that usually presents as persistent dryness of the eyes and mouth [205, 206]. Its clinical spectrum extends from an autoimmune exocrinopathy to a systemic involvement with vasculitis and diverse extraglandular systemic manifestations (40–50%). This includes CVD although with lower prevalence as mentioned above [207, 208]. Chronic systemic inflammation is a risk factor for developing AT, however, and contrary to what is expected, the prevalence of CVD associated with AT is not appreciably increased in patients with SS. This probably is characterized by chronic but milder inflammation as Ramos-Casals et al. showed [205]. In fact, Akyel et al. [209] found endothelial dysfunction in SS patients although their carotid IMT was comparable to the healthy
control group. It should be noted that the CV risk in patients with SS is rising as a result of the population affected by the disease (i.e., postmenopausal women) [43, 210]. Vaudo et al. [211] found a high rate of subclinical AT due to changes in the carotid arterial wall studied/seen by femoral and carotid ultrasonography. All these findings (i.e., Table 4) suggest that a functional impairment of the arterial wall may sustain early phases of atherosclerotic damage in SS. A combined effect of disease-related chronic inflammatory and immunological factors appears to support dysfunction of endothelium and vascular smooth muscle cells, respectively. Table 4 contains the most frequent traditional and nontraditional risk factors related to CVD and SS. The management of CVD in SS patients must be directed toward rigorous intervention of modifiable risk factors as well as nontraditional risk factors, warranting a routine evaluation of autoantibodies and other SS-related factors. Pérez-De-Lis et al. [210] found a protective role of AMs in CVD and SS patients since these drugs show an association with a lower frequency of HTN, T2DM, and dyslipidemia. So, in the future, it will be necessary to analyze the incidence of CVD and the role of the different risk factors listed in Table 4 prospectively for the development of such complications.

4.6. Systemic Sclerosis. There are two major disease presentations: the microvascular and macrovascular involvement. The vasculopathy of SSc typically affects the small arteries and capillaries (i.e., microvascular occlusive disease with vasospasm and intimal proliferation) while macrovascular disease has been demonstrated by carotid ultrasonography, ankle brachial blood pressure index, and peripheral angiography [48, 50, 52] due to fibrosis, thickening, and chronic proliferation of the intimal layer as well as transmural lymphocytic infiltrate without evidence of atherosclerotic plaque [48, 53]. However, recently, the evidence has demonstrated increased atherosclerosis, including CAC, higher prevalence of subclinical CAD, and higher carotid IMT [46, 212]. Patchy fibrosis is the most important feature in the myocardium, which is localized when it is subendocardial regions. This fibrosis usually accompanies LVDD [59, 60], but it is symptomatic in 10% of the cases [213]. There have been reported MI or myocardial perfusion defects with coronary arteries which suggests that the etiology of infarction may be due to microvascular disease rather than coronary AT although we must recognize that the latter is higher in patients with SSc [214, 215]. Patients with SSc have a reduced coronary flow reserve [216, 217], which is associated with higher coronary events [218, 219]. Other authors have reported ectasia, spasm, and coronary artery stenosis [56, 57]. Arrhythmias and conduction disturbances are characteristic of cardiac involvement in SSc as hypertrophy and heart failure contractility [58, 60] have been reported. Ultrasonography evaluation is also used to evaluate the carotid arteries and has been proven to be a useful marker for the assessment of subclinical AT and a strong predictor of subsequent MI and CVA [77, 216, 220]. In addition, once SSc has been diagnosed and established, attention to treatment of the vascular component is critical. While the traditional approach has been solely to use vasodilator therapy, new investigations are underway to develop novel therapies, to prevent further vascular injury, and to stimulate vascular repair. Some of the current treatment approaches include the following: prostacyclin analogs, endothelin antagonists, phosphodiesterase inhibitors, immunosuppressive therapy, and tyrosine kinase inhibitors [221].

4.7. Spondyloarthropathies. Since spondyloarthropathies are also chronic autoimmune-autoinflammatory diseases associated with accelerated atherosclerosis, the patients with spondyloarthropathies also have a higher risk of cardiovascular disease than the general population. Ankylosing spondylitis has been associated with increased mortality rate compared to the general population, which is, in great part, the result of cardiovascular complications. Also, subclinical atherosclerosis, manifested by the presence of endothelial dysfunction and increased carotid intima-media wall thickness and carotid plaques, has been observed in patients with psoriatic arthritis and ankylosing spondylitis. In patients with ankylosing spondylitis, TNF-alpha blockade was associated with improvement of insulin resistance, markers of metabolic syndrome, and biomarkers of endothelial dysfunction [222–232].

5. Conclusions

AT and ADs share several mechanisms. The excessive CV events observed in patients with ADs are not fully explained by classic risk factors. Several novel risk factors contribute to development of premature vascular damage. Therefore, a complex interaction between traditional and disease-specific traits converges into a shared proatherogenic phenotype in this population. Until additional research and disease-specific risk prediction tools are available, current evidence supports aggressive treatment of disease activity and careful screening for and management of modifiable traditional risk factors in patients with ADs. The finding and understanding of complex interactions between predisposing factors (i.e., genetic, environmental factors, and ADs per se) will allow us to better describe and assess the broad spectrum of CV subphenotypes in ADs and their treatments.

Conflict of Interests

The authors have indicated that they have no conflict of interests regarding the content of this paper.

Acknowledgments

The authors thank their colleagues at the Center for Autoimmune Diseases Research (CREA), for fruitful discussions. This work was supported by the School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia.
[64] N. S. Wade and A. S. Major, “The problem of accelerated atherosclerosis in systemic lupus erythematosus: insights into a complex co-morbidity,” *Thrombosis and Haemostasis*, vol. 106, no. 5, pp. 849–857, 2011.

[65] G. Wick, M. Knollach, and Q. Xu, “Autoimmune and inflammatory mechanisms in atherosclerosis,” *Annual Review of Immunology*, vol. 22, pp. 361–403, 2004.

[66] E. Matsuura, “Atherosclerosis and autoimmunity,” *Clinical Reviews in Allergy & Immunology*, vol. 37, no. 1, pp. 1–3, 2009.

[67] I. del Rincón, D. H. O’Leary, G. L. Freeman, and A. Escalante, “Acceleration of atherosclerosis during the course of rheumatoid arthritis,” *Atherosclerosis*, vol. 195, no. 2, pp. 354–360, 2007.

[68] P. A. Gordon, J. George, M. A. Khamashta, D. Harats, G. Hughes, and Y. Shoenfeld, “Atherosclerosis and autoimmunity,” *Lupus*, vol. 10, no. 4, pp. 249–252, 2001.

[69] Y. Sherer and Y. Shoenfeld, “Mechanisms of disease: atherosclerosis in autoimmune diseases,” *Nature Clinical Practice Rheumatology*, vol. 2, no. 2, pp. 99–106, 2006.

[70] J. Frostegård, “Atherosclerosis in patients with autoimmune disorders,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 25, pp. 1776–1785, 2005.

[71] M. Níkpour, P. J. Harvey, D. Ibanez, D. D. Gladman, and M. B. Urowitz, “High-sensitivity C-reactive protein as a marker of cardiovascular risk in systemic lupus erythematosus,” *Arthritis and Rheumatism*, vol. 64, no. 9, pp. 3052–3053, 2012.

[72] S. G. O’Neill, D. A. Isenberg, and A. Rahman, “Could antibodies to C-reactive protein link inflammation and cardiovascular disease in patients with systemic lupus erythematosus?” *Annals of the Rheumatic Diseases*, vol. 66, no. 8, pp. 898–991, 2007.

[73] B. Galarraga, F. Khan, P. Kumar, T. Pullar, and J. J. F. Belch, “C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis,” *Rheumatology*, vol. 47, no. 12, pp. 1780–1784, 2008.

[74] K. Maksimowicz-McKinnon, L. S. Magder, and M. Petri, “Predictors of carotid atherosclerosis in systemic lupus erythematosus,” *Journal of Rheumatology*, vol. 33, no. 12, pp. 2458–2463, 2006.

[75] M. A. Gonzalez-Gay, C. Gonzalez-Juanatey, A. Pitóiero, C. Garcia-Porrua, A. Testa, and J. Llorca, “High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with systemic lupus erythematosus,” *Lupus*, vol. 13, no. 12, pp. 927–933, 2004.

[76] S. Martinez-Berriotxoa, G. Ruiz-Irastorza, M. V. Egurbide, M. Rueda, and C. Aguirre, “Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus,” *Lupus*, vol. 13, no. 12, pp. 927–933, 2004.

[77] F. Bartoli, C. Angotti, C. Fatini et al., “Angiotensin-converting enzyme I/D polymorphism and macrovascular disease in systemic sclerosis,” *Rheumatology*, vol. 46, no. 5, pp. 772–775, 2007.

[78] L. Rodríguez-Rodriguez, R. López-Mejías, M. García-Bermúdez, C. González-Juanatey, M. A. González-Gay, and I. Martín, “Genetic markers of cardiovascular disease in rheumatoid arthritis,” *Mediators of Inflammation*, vol. 2012, Article ID 574817, 14 pages, 2012.

[79] S.-H. Kim, C.-K. Lee, E. Y. Lee et al., “Serum oxidized low-density lipoproteins in rheumatoid arthritis,” *Rheumatology International*, vol. 24, no. 4, pp. 230–233, 2004.

[80] R. López-Mejías, F. Genre, C. González-Juanatey, and M. A. González-Gay, “Autoantibodies and biomarkers of endothelial cell activation in atherosclerosis,” *Vasa*, vol. 43, no. 2, pp. 83–85, 2014.

[81] S. Sayols-Baxeras, C. Lluís-Ganella, G. Lucas, and R. Eloua, “Pathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variants,” *The Application of Clinical Genetics*, vol. 7, pp. 15–32, 2014.

[82] R. Ross, “Atherosclerosis—an inflammatory disease,” *The New England Journal of Medicine*, vol. 340, no. 2, pp. 115–126, 1999.

[83] C. López-Pedrera, C. Pérez-Sánchez, M. Ramos-Casals, M. Santos-Gonzalez, A. Rodríguez-Ariza, and M. José Cuadrado, “Cardiovascular risk in systemic autoimmune diseases: epigenetic mechanisms of immune regulatory functions,” *Clinical and Developmental Immunology*, vol. 2012, Article ID 974648, 10 pages, 2012.

[84] M. Ferencik, V. Vstrtinová, and I. Hulin, “Defects in regulation of local immune responses resulting in atherosclerosis,” *Clinical and Developmental Immunology*, vol. 12, pp. 225–234, 2005.

[85] E. E. Emsen, M. Shen, C. G. H. Bell, and A. Qureshi, “Inhibition of atherosclerosis in CD4 T-cell-ablated and nude (nu/nu) C57BL/6 hyperlipidemic mice,” *The American Journal of Pathology*, vol. 149, no. 2, pp. 675–685, 1996.

[86] M. García-Bermúdez, C. González-Juanatey, R. López-Mejías et al., “Study of association of CD40–CD154 gene polymorphisms with disease susceptibility and cardiovascular risk in Spanish rheumatoid arthritis patients,” *PloS ONE*, vol. 7, p. e94921, 2012.

[87] Y. Sherer, A. Tenenbaum, S. Praprontik et al., “Coronary artery disease but not coronary calcification is associated with elevated levels of cardiolipin, beta-2-glycoprotein-I, and oxidized LDL antibodies,” *Cardiology*, vol. 95, no. 1, pp. 20–24, 2001.

[88] T. Inoue, T. Uchida, H. Kamishirado, K. Takayanagi, and S. Morooka, “Antibody against oxidized low density lipoprotein may predict progression or regression of atherosclerotic coronary artery disease,” *Journal of the American College of Cardiology*, vol. 37, no. 7, pp. 1871–1876, 2001.

[89] A. O. Santos, F. A. H. Fonseca, S. M. Fischer, C. M. C. Monteiro, S. A. B. Brandão, and R. M. S. Póvoa, “High circulating autoantibodies against human oxidized low-density lipoprotein are related to stable and lower titers to unstable clinical situation,” *Clinica Chimica Acta*, vol. 406, pp. 113–118, 2009.

[90] J. Che, G. Li, W. Wang et al., “Serum autoantibodies against human oxidized low-density lipoproteins are inversely associated with severity of coronary stenotic lesions calculated by Gensini score,” *Cardiology Journal*, vol. 18, no. 4, pp. 364–370, 2011.

[91] E. Matsuura, K. Kobayashi, K. Inoue, L. R. Lopez, and Y. Shoenfeld, “Oxidized LDL/β2-glycoprotein I complexes: New aspects in atherosclerosis,” *Lupus*, vol. 14, no. 9, pp. 736–741, 2005.

[92] A. Gürlek, C. Ozdöl, G. Pamir, I. Dinçer, H. Tutkak, and D. Oral, “Association between anticardiolipin antibodies and recurrent cardiac events in patients with acute coronary syndrome,” *International Heart Journal*, vol. 46, pp. 631–638, 2005.

[93] B. Nowak, M. Szymyrka-Kaczmarek, A. Durazińska et al., “Anti-Ox-LDL antibodies and anti-Ox-LDL-B2GPI antibodies in patients with systemic lupus erythematosus,” *Advances in Clinical and Experimental Medicine*, vol. 21, no. 3, pp. 331–335, 2012.

[94] E. Cucurrull, L. R. Espinoza, E. Mendez, J. F. Molina, J. Ordí-Ros, and A. E. Gharavi, “Anticardiolipin and anti-β2glycoprotein-I antibodies in patients with systemic lupus erythematosus: comparison between Colombians and Spaniards,” *Lupus*, vol. 8, no. 2, pp. 134–141, 1999.

[95] M. Dieudé, J. A. Correa, C. Neville et al., “Association of autoantibodies to heat-shock protein 60 with arterial vascular
events in patients with antiphospholipid antibodies," *Arthritis and Rheumatism*, vol. 63, no. 8, pp. 2416–2424, 2011.

[96] H. Zinger, Y. Sherer, and Y. Shoenfeld, "Atherosclerosis in autoimmune rheumatic diseases—mechanisms and clinical findings," *Clinical Reviews in Allergy & Immunology*, vol. 37, no. 1, pp. 20–28, 2009.

[97] A. Rojas-Villarraga, O. Ortega-Hernandez, L. F. Gomez et al., "Risk factors associated with different stages of atherosclerosis in Colombian patients with rheumatoid arthritis," *Seminars in Arthritis and Rheumatism*, vol. 38, no. 2, pp. 71–82, 2008.

[98] A. N. DeMaria, "Relative risk of cardiovascular events in patients with rheumatoid arthritis," *The American Journal of Cardiology*, vol. 89, no. 6, pp. 33D–38D, 2002.

[99] S. Hannawi, B. Haluska, T. H. Marwick, and R. Thomas, "Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation," *Arthritis Research and Therapy*, vol. 9, article R16, 2007.

[100] D. P. M. Symmons and S. E. Gabriel, "Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE," *Nature Reviews Rheumatology*, vol. 7, no. 7, pp. 399–408, 2011.

[101] C. Gonzalez-Juanatey, J. Llorca, A. Testa, J. Revuelta, C. Gonzalez-Juanatey, J. Llorca, A. Testa, J. Revuelta, C. Garcia-Porrua, and M. A. Gonzalez-Gay, "Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease," *Medicine*, vol. 82, no. 6, pp. 407–413, 2003.

[102] C. Gonzalez-Juanatey, J. Llorca, and M. A. Gonzalez-Gay, "Correlation between endothelial function and carotid atherosclerosis in rheumatoid arthritis patients with long-standing disease," *Arthritis Research & Therapy*, vol. 13, no. 3, article R101, 2011.

[103] V. R. da Cunha, C. V. Brenol, J. C. T. Brenol, and R. M. Xavier, "Rheumatoid arthritis and metabolic syndrome," *Revista Brasileira de Reumatologia*, vol. 51, no. 3, pp. 260–268, 2011.

[104] M. Cisternas, M. A. Gutiérrez, J. Klaassen, A. M. Acosta, and S. Jacobelli, "Cardiovascular risk factors in Chilean patients with rheumatoid arthritis," *Journal of Rheumatology*, vol. 29, no. 8, pp. 1619–1622, 2002.

[105] P. Sarzi-Puttini, F. Atzeni, R. Gerli et al., "Cardiac involvement in systemic rheumatic diseases: an update," *Autoimmunity Reviews*, vol. 9, no. 12, pp. 849–852, 2010.

[106] M. Chan, "Global status report on noncommunicable diseases," *World Heal Organ*, 2010.

[107] D. Yach, C. Hawkes, C. L. Gould, and K. J. Hofman, "The global burden of chronic diseases: overcoming impediments to prevention and control," *The Journal of the American Medical Association*, vol. 291, no. 21, pp. 2616–2622, 2004.

[108] D. H. Solomon, E. W. Karlson, E. B. Rimm et al., "Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis," *Circulation*, vol. 107, no. 9, pp. 1303–1307, 2003.

[109] J. A. Aviña-Zubieta, H. K. Choi, M. Sadatsafavi, M. Etmianan, J. M. Esdaile, and D. Lacaille, "Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies," *Arthritis Care and Research*, vol. 59, no. 12, pp. 1690–1697, 2008.

[110] H. Maradit-Kremers, C. S. Crowson, P. J. Nicola et al., "Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study," *Arthritis and Rheumatism*, vol. 52, no. 2, pp. 402–411, 2005.

[111] Y. Santiago-Casas, T. Gonzalez-Rivera, L. Castro-Santana, G. Rios, and V. Rodriguez, "Impact of age on clinical manifestations and outcome in Puerto Ricans with rheumatoid arthritis," *Ethnicity & Disease*, vol. 20, no. 1, supplement 1, pp. SI–S95, 2010.

[112] I. Pereira, I. Laurindo, R. Burlingame et al., "Auto-antibodies do not influence development of atherosclerotic plaques in rheumatoid arthritis," *Joint Bone Spine*, vol. 75, no. 4, pp. 416–421, 2008.

[113] V. R. da Cunha, C. V. Brenol, J. C. T. Brenol et al., "Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity," *Scandinavian Journal of Rheumatology*, vol. 41, no. 3, pp. 186–191, 2012.

[114] R. Pineda-Tamayo, G. Arcila, P. Restrepo, and J. M. Anaya, "Impact of cardiovascular illness on hospitalization costs in patients with rheumatoid arthritis," *Biomedica*, vol. 24, no. 4, pp. 366–374, 2004.

[115] O. D. Ortega-Hernandez, R. Pineda-Tamayo, A. L. Pardo, A. Rojas-Villarraga, and J. M. Anaya, "Cardiovascular disease is associated with extra-articular manifestations in patients with rheumatoid arthritis," *Clinical Rheumatology*, vol. 28, no. 7, pp. 767–775, 2009.

[116] M. Larroude and A. Romanowicz, "Artritis reumatoidea y aterosclerosis," *Revista Argentina de Reumatología*, vol. 14, pp. 16–24, 2003.

[117] C. Lascano, P. Alba, C. Gobbi et al., "Disfunción diastólica ventricular izquierda en la artritis reumatoide," *Revista de la Facultad de Ciencias Medicas*, vol. 66, pp. 58–65, 2009.

[118] R. R. Acosta, C. Castell, M. Hernández, and A. Pernas, "Comorbilidad y mortalidad en una cohorte de pacientes cubanos con artritis reumatoide," *Revista Cubana de Medicina*, vol. 48, pp. 1–12, 2009.

[119] C. Gomez-Vaquero, A. Corrales, A. Zacarias et al., "SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis," *Arthritis Research & Therapy*, vol. 15, article R91, 2013.

[120] A. Corrales, C. Gonzalez-Juanatey, M. E. Peiró, R. Blanco, J. Llorca, and M. A. Gonzalez-Gay, "Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study," *Annals of the Rheumatic Diseases*, vol. 73, pp. 722–727, 2014.

[121] X. Sheng, M. J. Murphy, T. M. MacDonald, and L. Wei, "Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis," *Journal of Rheumatology*, vol. 39, no. 1, pp. 32–40, 2012.

[122] M. A. De Vera, H. Choi, M. Abrahamowicz, J. Kopec, and D. Lacaille, "Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: a population-based study," *Arthritis Care and Research*, vol. 64, no. 6, pp. 809–816, 2012.

[123] A. J. Flammer, I. Sudano, F. Hermann et al., "Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis," *Circulation*, vol. 117, no. 17, pp. 2262–2269, 2008.

[124] M. J. L. Peters, D. P. M. Symmons, D. McCarey et al., "EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis," *Annals of the Rheumatic Diseases*, vol. 69, no. 2, pp. 325–331, 2010.

[125] F. Atzeni, M. Turiel, R. Caporali et al., "The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases," *Autoimmunity Reviews*, vol. 9, no. 12, pp. 835–839, 2010.
[126] W. G. Dixon, K. D. Watson, M. Lunt et al., “Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register,” *Arthritis and Rheumatism*, vol. 56, no. 9, pp. 2905–2912, 2007.

[127] V. P. van Halm, M. T. Nurmohamed, J. W. R. Twisk, B. A. C. Dijkman, and A. E. Voskuyl, “Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study,” *Arthritis Research and Therapy*, vol. 8, article R151, 2006.

[128] H. K. Choi, M. A. Hernández, J. D. Seeger, J. M. Robbins, and F. Wolfe, “Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study,” *Lancet*, vol. 359, pp. 1173–1177, 2002.

[129] A. B. Reiss, S. E. Carson, K. Anwar et al., “Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages,” *Arthritis & Rheumatism*, vol. 58, no. 12, pp. 3675–3683, 2008.

[130] G. J. Pons-Estel, G. S. Alarcón, L. Hachuel et al., “Anti-malarials exert a protective effect while mizotero patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort,” *Rheumatology*, vol. 51, no. 7, pp. 1293–1298, 2012.

[131] I. Ben-Zvi, S. Kivity, P. Langevitz, and Y. Shoenfeld, “Hydroxychloroquine: from malaria to autoimmunity,” *Clinical Reviews in Allergy and Immunology*, vol. 42, no. 2, pp. 145–153, 2012.

[132] M. A. Martín-Martínez, C. González-Juanatey, S. Castañeda et al., “Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis: scientific evidence and expert opinion,” *Seminars in Arthritis and Rheumatism*, 2014.

[133] Z. Al-Aly, H. Pan, A. Zeringue et al., “Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis,” *Translational Research*, vol. 157, no. 1, pp. 10–18, 2011.

[134] L.-S. Tam, G. D. Kitas, and M. A. González-Gay, “Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis?” *Rheumatology*, 2014.

[135] M. A. Gonzalez-Gay, J. M. de Matías, C. Gonzalez-Juanatey et al., “Anti-tumor necrosis factor-α blockade improves insulin resistance in patients with rheumatoid arthritis,” *Clinical and Experimental Rheumatology*, vol. 24, no. 1, pp. 83–86, 2006.

[136] M. A. Gonzales-Gay, M. T. Garcia-UNzueta, J. M. de Matías et al., “Influence of anti-TNF-α infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis,” *Clinical and Experimental Rheumatology*, vol. 24, no. 4, pp. 373–379, 2006.

[137] C. Gonzalez-Juanatey, J. Llorca, A. Sanchez Andrade, C. Garcia-Porrua, J. Martin, and M. A. Gonzalez-Gay, “Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab,” *Clinical and Experimental Rheumatology*, vol. 24, no. 3, pp. 309–312, 2006.

[138] C. Gonzalez-Juanatey, T. R. Vazquez-Rodriguez, J. A. Miranda-Filloy et al., “Anti-TNF-α adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy,” *Mediators of Inflammation*, vol. 2012, Article ID 674265, 8 pages, 2012.

[139] O. Schultz, F. Oberhauser, J. Saech et al., “Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (A) levels in human subjects with rheumatoid diseases,” *PLoS ONE*, vol. 5, no. 12, Article ID e14328, 2010.

[140] C. Gonzalez-Juanatey, J. Llorca, T. R. Vazquez-Rodriguez, N. Diaz-Varela, H. Garcia-Quiraga, and M. A. Gonzalez-Gay, “Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor α blocker therapy,” *Arthritis Care and Research*, vol. 59, no. 12, pp. 1821–1824, 2008.

[141] S. G. Guerra, T. J. Vyse, and D. S. C. Graham, “The genetics of lupus: a functional perspective,” *Arthritis Research & Therapy*, vol. 14, no. 3, article 211, 2012.

[142] J. R. Eliott and S. Manzi, “Cardiovascular risk assessment and treatment in systemic lupus erythematosus,” *Best Practice and Research: Clinical Rheumatology*, vol. 23, no. 4, pp. 481–494, 2009.

[143] M. B. Urowitz, A. A. M. Bookman, B. E. Koehler, D. A. Gordon, H. A. Smythe, and M. A. Ogryzlo, “The bimoal mortality pattern of systemic lupus erythematosus,” *The American Journal of Medicine*, vol. 60, no. 2, pp. 221–225, 1976.

[144] L. Björnadal, L. Yin, F. Granath, L. Klareskog, and A. Ekborn, “Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964–95,” *Journal of Rheumatology*, vol. 31, no. 4, pp. 713–719, 2004.

[145] P. Soltész, G. Kerekes, H. Dérij et al., “Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment,” *Autoimmunity Reviews*, vol. 10, pp. 416–425, 2011.

[146] M. M. Ward, “Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus,” *Arthritis and Rheumatism*, vol. 42, pp. 338–346, 1999.

[147] T. Thompson, K. Sutton-Tyrrell, R. P. Wildman et al., “Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus,” *Arthritis and Rheumatism*, vol. 58, no. 3, pp. 835–842, 2008.

[148] B. Zöller, X. Li, J. Sundquist, and K. Sundquist, “Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden,” *BMC Neurology*, vol. 12, article 41, 2012.

[149] S. Manzi, E. N. Meilahn, J. E. Rairie et al., “Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study,” *The American Journal of Epidemiology*, vol. 145, no. 5, pp. 408–415, 1997.

[150] L. M. Fischer, R. G. Schlienger, C. Matter, H. Jick, and C. R. Meier, “Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of First-Time acute myocardial infarction,” *American Journal of Cardiology*, vol. 93, no. 2, pp. 198–200, 2004.

[151] A. E. Hak, E. W. Karlson, D. Feskanich, M. J. Stampfer, and K. H. Costenbader, “Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses’ health study,” *Arthritis Care and Research*, vol. 61, no. 10, pp. 1396–1402, 2009.

[152] C. Bengtsson, M.-L. ¨Ohman, O. Nived, and S. R. Rantap¨a¨a, “Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study,” *Lupus*, vol. 21, no. 4, pp. 452–459, 2012.

[153] M. B. Urowitz, D. Gladman, D. Ibañez et al., “Atherosclerotic vascular events in a multinational inception cohort of systemic
lupus erythematosus," *Arthritis Care and Research*, vol. 62, no. 6, pp. 881–887, 2010.

[154] P. I. Burgos, L. M. Vilá, J. D. Revelle, and G. S. Alarcón, “Peripheral vascular damage in systemic lupus erythematosus: data from LUMINA, a large multi-ethnic U.S. cohort (LXIX),” *Lupus*, vol. 18, no. 14, pp. 1303–1308, 2009.

[155] M. Petri, S. Perez-Guthmann, D. Spence, and M. C. Hochberg, “Risk factors for coronary artery disease in patients with systemic lupus erythematosus,” *The American Journal of Medicine*, vol. 93, no. 5, pp. 513–519, 1992.

[156] M. B. Urowitz, D. Ibañez, and D. D. Gladman, “Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors,” *Journal of Rheumatology*, vol. 34, no. 1, pp. 70–75, 2007.

[157] J. Gustafsson, I. Gunnarsson, O. Börjesson et al., “Predictors of the first cardiovascular event in patients with systemic lupus erythematosus—a prospective cohort study,” *Arthritis Research & Therapy*, vol. 11, no. 6, article R186, 2009.

[158] E. Svensson, K. Jensen-Urstad, M. Heimbürger et al., “Risk factors for cardiovascular disease in systemic lupus erythematosus,” *Circulation*, vol. 104, no. 16, pp. 1887–1893, 2001.

[159] M. J. Roman, J. E. Salmon, R. Sobel et al., “Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome,” *American Journal of Cardiology*, vol. 87, no. 5, pp. 663–666, 2001.

[160] J. Amaya-Amaya, J. C. Sarmiento-Monroy, J. Caro-Moreno et al., “Cigarette smoking and coffee consumption independently influence the risk of developing cardiovascular disease in systemic lupus erythematosus,” *Lupus*, vol. 22, no. 6, 2013.

[161] J. M. Esdaile, M. Abrahamowicz, T. Grodzicky et al., “Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus,” *Arthritis & Rheumatology*, vol. 44, no. 10, pp. 2331–2337, 2001.

[162] P. E. Westerweel, R. K. A. C. Luyten, H. A. Koomans, R. H. W. M. Derksen, and M. C. Verhaar, “Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus,” *Arthritis and Rheumatism*, vol. 56, no. 5, pp. 1384–1396, 2007.

[163] E. Y. Rhew and R. Ramsey-Goldman, “Premature atherosclerotic disease in systemic lupus erythematosus: role of inflammatory mechanisms,” *Autoimmunity Reviews*, vol. 5, no. 2, pp. 101–105, 2006.

[164] M. McMahon, B. H. Hahn, and B. J. Skaggs, “Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention,” *Expert Review of Clinical Immunology*, vol. 7, no. 5, pp. 227–241, 2011.

[165] M. Nikpour, M. B. Urowitz, and D. D. Gladman, “Premature atherosclerosis in systemic lupus erythematosus,” *Rheumatic Disease Clinics of North America*, vol. 31, no. 2, pp. 329–354, 2005.

[166] L. E. Full, C. Ruisanchez, and C. Monaco, “The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus,” *Arthritis Research & Therapy*, vol. 11, no. 2, p. 217, 2009.

[167] J. R. Elliott, S. Manzi, and D. Edmundowicz, “The role of preventive cardiology in systemic lupus erythematosus,” *Current Rheumatology Reports*, vol. 9, no. 2, pp. 125–130, 2007.

[168] I. N. Bruce, “Cardiovascular disease in lupus patients: Should all patients be treated with statins and aspirin?” *Best Practice and Research: Clinical Rheumatology*, vol. 19, no. 5, pp. 823–838, 2005.

[169] S. J. Katz and A. S. Russell, “Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action,” *Current Opinion in Rheumatology*, vol. 23, no. 3, pp. 278–281, 2011.

[170] S. J. Morris, M. C. M. Wasko, J. L. Antohe et al., “Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients,” *Arthritis Care & Research*, vol. 63, no. 4, pp. 530–534, 2011.

[171] R. Kaiser, C. M. Cleveland, and L. A. Criswell, “Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort,” *Annals of the Rheumatic Diseases*, vol. 68, no. 2, pp. 238–241, 2009.

[172] H. Jung, R. Bobba, J. Su et al., “The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus,” *Arthritis and Rheumatism*, vol. 62, no. 3, pp. 863–868, 2010.

[173] M. Petri, “Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients,” *Current Rheumatology Reports*, vol. 13, no. 1, pp. 77–80, 2011.

[174] G. S. Alarcón, G. McGwin, A. M. Bertoli et al., “Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multietnic US cohort (LUMINA L),” *Annals of the Rheumatic Diseases*, vol. 66, no. 9, pp. 1168–1172, 2007.

[175] G. Ruiz-Irastorza, M. V. Egurbide, J. I. Pijoan et al., “Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus,” *Lupus*, vol. 15, no. 9, pp. 577–583, 2006.

[176] M. Nikpour, M. B. Urowitz, D. Ibanez, P. J. Harvey, and D. D. Gladman, “Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study,” *Arthritis Research & Therapy*, vol. 13, article R156, 2011.

[177] C. C. Belizna, V. Richard, C. Thuillez, H. Lévesque, and Y. Shoenfeld, “Insights into atherosclerosis therapy in antiphospholipid syndrome,” *Autoimmunity Reviews*, vol. 7, no. 1, pp. 46–51, 2007.

[178] M. J. Roman, B.-A. Shanker, A. Davis et al., “Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus,” *The New England Journal of Medicine*, vol. 349, no. 25, pp. 2399–2406, 2003.

[179] S. M. Greenstein, S. Sun, T. M. Calderon et al., “Mycophenolate mofetil treatment reduces atherosclerosis in the cholesterol-fed rabbit,” *Journal of Surgical Research*, vol. 91, no. 2, pp. 123–129, 2000.

[180] B. Giannakopoulos and S. A. Kritis, “The pathogenesis of the antiphospholipid syndrome,” *The New England Journal of Medicine*, vol. 368, no. 11, pp. 1033–1044, 2013.

[181] F. Tenedios, D. Erkan, and M. D. Lockshin, “Cardiac involvement in the antiphospholipid syndrome,” *Lupus*, vol. 14, no. 9, pp. 691–696, 2005.

[182] L. J. Jara, G. Medina, and O. Vera-Lastra, “Systemic antiphospholipid syndrome and atherosclerosis,” *Autoimmunity Reviews*, vol. 13, no. 9, pp. 691–696, 2014.

[183] A. Tufano, A. Guida, M. N. D. Di Minno, A. M. De Gregorio, A. M. Cerbone, and G. Di Minno, “Cardiovascular events in patients with antiphospholipid antibodies: Strategies of prevention,” *Nutrition, Metabolism and Cardiovascular Diseases*, vol. 20, no. 4, pp. 217–223, 2010.
P. J. Levy, C. F. Cooper, and M. F. Gonzalez, “Massive lower extremity arterial thrombosis and acute hepatic insufficiency in a young adult with premature atherosclerosis associated with hyperlipoprotein(a)emia and antiphospholipid syndrome: a case report,” Arteriology, vol. 46, no. 9, pp. 853–858, 1995.

C. K. Shortell, K. Ouriel, R. M. Green, J. J. Condemi, and J. A. DeWeese, “Vascular disease in the antiphospholipid syndrome: a comparison with the patient population with atherosclerosis,” Journal of Vascular Surgery, vol. 15, no. 1, pp. 158–166, 1992.

O. Vaara, M. Mänttäri, V. Manninen et al., “Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men,” Circulation, vol. 91, no. 1, pp. 23–27, 1995.

Y. Sherer and Y. Shoenfeld, “Antiphospholipid syndrome, antiphospholipid antibodies, and atherosclerosis,” Current Atherosclerosis Reports, vol. 3, no. 4, pp. 328–333, 2001.

A. Bili, A. J. Moss, C. W. Francis, W. Zareba, L. F. M. Watelet, and I. Sanz, “Anticardiolipin antibodies and recurrent coronary events: a prospective study of 1150 patients,” Circulation, vol. 102, no. 11, pp. 1258–1263, 2000.

P. Soltész, Z. Szekanecz, E. Kiss, and Y. Shoenfeld, “Cardiac manifestations in antiphospholipid syndrome,” Autoimmunity Reviews, vol. 6, no. 6, pp. 379–386, 2007.

I. Koniarí, S. N. Siminelakis, N. G. Baikoussis, G. Papadopoulos, J. Goudevenos, and E. Apostolakis, “Antiphospholipid syndrome: its implication in cardiovascular diseases: a review,” Journal of Cardiothoracic Surgery, vol. 5, no. 1, article 101, 2010.

M. Turiel, S. Muzzupappa, B. Gottardi, C. Crema, P. Sarzi-Puttini, and E. Rossi, “Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography,” Lupus, vol. 9, no. 6, pp. 406–412, 2000.

V. A. P. Hegde, Y. Vivas, H. Shah et al., “Cardiovascular surgical outcomes in patients with the antiphospholipid syndrome—a case-series,” Heart Lung and Circulation, vol. 16, no. 6, pp. 423–427, 2007.

Y. Shoenfeld, R. Gerli, A. Doria et al., “Accelerated atherosclerosis in autoimmune rheumatic diseases,” Circulation, vol. 112, no. 21, pp. 3337–3347, 2005.

R. G. Espinola, S. S. Pierangeli, A. E. Ghara, and E. N. Harris, “Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies,” Thrombosis & Haemostasis, vol. 87, no. 3, pp. 518–522, 2002.

C. Lopez-Pedrera, P. Ruiz-Limón, A. Valverde-Estepa, N. Barbaroja, and A. Rodriguez-Ariza, “To cardiovascular disease and beyond: New therapeutic perspectives of statins in autoimmune diseases and cancer,” Current Drug Targets, vol. 13, no. 6, pp. 829–841, 2012.

P. L. Meroni, E. Raschi, C. Testoni et al., “Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype,” Arthritis & Rheumatology, vol. 44, pp. 2870–2878, 2001.

S. Dunoyer-Geindre, B. R. Kwak, G. Pelli et al., “Immunization of LDL receptor-deficient mice with beta2-glycoprotein I or human serum albumin induces a more inflammatory phenotype in atherosclerotic plaques,” Thrombosis and Haemostasis, vol. 97, no. 1, pp. 129–138, 2007.

U. Laufs, V. La Fata, J. Plutzky, and J. K. Liao, “Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors,” Circulation, vol. 97, no. 12, pp. 1129–1135, 1998.

I. N. Bruce, “Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin?” Best Practice and Research: Clinical Rheumatology, vol. 19, no. 5, pp. 823–838, 2005.

E. C. Jury and M. R. Ehrenstein, “Statins: immunomodulators for autoimmune rheumatic disease?” Lupus, vol. 14, no. 3, pp. 192–196, 2005.

S. Dunoyer-Geindre, E. K. O. Kruthof, F. Boehlen, N. Satta-Poschung, G. Reber, and P. de Moerloose, “Aspirin inhibits endothelial cell activation induced by antiphospholipid antibodies,” Journal of Thrombosis and Haemostasis, vol. 2, no. 7, pp. 1176–1181, 2004.

N. Grosser and H. Schröder, “Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 8, pp. 1345–1351, 2003.

S. Baldus, V. Rudolph, M. Roiss et al., “Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase,” Circulation, vol. 113, no. 15, pp. 1871–1878, 2006.

C. Comarmond and P. Cacoub, “Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies,” Autoimmunity Reviews, vol. 12, no. 7, pp. 752–757, 2013.

M. Ramos-Casals, A. G. Tzioufas, and J. Font, “Primary Sjögren’s syndrome: new clinical and therapeutic concepts,” Annals of the Rheumatic Diseases, vol. 64, no. 3, pp. 347–354, 2005.

S. S. Kassan and H. M. Moutsopoulos, “Clinical manifestations and early diagnosis of Sjögren syndrome,” Archives of Internal Medicine, vol. 164, no. 12, pp. 1275–1284, 2004.

A. L. Fauchais, B. Ouattara, G. Gondran, F. Lalloué, D. Petit, and K. Ly, “Articular manifestations in primary Sjögren’s syndrome: clinical significance and prognosis of 188 patients,” Rheumatology, vol. 49, pp. 1164–1172, 2010.

M. Ramos-Casals, P. Brito-Zerón, and J. Font, “The overlap of Sjögren’s syndrome with other systemic autoimmune diseases,” Seminars in Arthritis and Rheumatism, vol. 36, no. 4, pp. 246–255, 2007.

A. Akyel, Y. Tavil, C. Yayla et al., “Endothelial dysfunction in primary Sjögren syndrome,” West Indian Medical Journal, vol. 61, pp. 81–870, 2012.

M. Pérez-De-Lis, M. Akubi, A. Sisó et al., “Cardiovascular risk factors in primary Sjögren’s syndrome: a case-control study in 624 patients,” Lupus, vol. 19, pp. 941–948, 2010.

G. Vaudo, E. B. Bocci, Y. Shoenfeld et al., “Precocious intima-media thickening in patients with primary Sjögren’s syndrome,” Arthritis & Rheumatism, vol. 52, no. 12, pp. 3890–3897, 2005.

K. Au, M. K. Singh, V. Bodukam et al., “Atherosclerosis in systemic sclerosis: a systematic review and meta-analysis,” Arthritis and Rheumatism, vol. 63, no. 7, pp. 2078–2090, 2011.

M. R. Akram, C. E. Handler, M. Williams et al., “Angiographically proven coronary artery disease in scleroderma,” Rheumatology, vol. 45, no. 11, pp. 1395–1398, 2006.

V. Khurma, C. Meyer, G. S. Park, M. McMahon, J. Lin, and R. R. Singh, “A pilot study of subclinical coronary atherosclerosis in systemic sclerosis: coronary artery calcification in cases and controls,” Arthritis and Rheumatology, vol. 59, pp. 591–597, 2008.

A. Kahan and Y. Allanore, “Primary myocardial involvement in systemic sclerosis,” Rheumatology, vol. 45, supplement 4, pp. iv14–iv17, 2006.
Y. Sherer, M. M. Cerinic, F. Bartoli et al., “Early atherosclerosis in systemic sclerosis,” *Annals of the New York Academy of Sciences*, vol. 1108, pp. 283–290, 2007.

R. Montisci, A. Vacca, P. Garau et al., “Detection of early impairment of coronary flow reserve in patients with systemic sclerosis,” *Annals of the Rheumatic Diseases*, vol. 62, no. 9, pp. 890–893, 2003.

G. Szücs, O. Tímár, Z. Szekanecz et al., “Endothelial dysfunction precedes atherosclerosis in systemic sclerosis—relevance for prevention of vascular complications,” *Rheumatology*, vol. 46, no. 5, pp. 759–762, 2007.

M. E. Hettema, H. Bootsma, and C. G. M. Kaltenberg, “Macrovascular disease and atherosclerosis in SSc,” *Rheumatology*, vol. 47, no. 5, pp. 578–583, 2008.

Y. Sherer, M. M. Cerinic, F. Bartoli et al., “Early atherosclerosis and autoantibodies to heat-shock proteins and oxidized LDL in systemic sclerosis,” *Annals of the New York Academy of Sciences*, vol. 1108, pp. 259–267, 2007.

M. Matucci-Cerinic, B. Kahaleh, and F. M. Wigley, “Review: evidence that systemic sclerosis is a vascular disease,” *Annals of the New York Academy of Sciences*, vol. 1108, pp. 259–267, 2007.

F. Genre, R. López-Mejías, J. A. Miranda-Filloy et al., “Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients,” *Annals of the Rheumatic Diseases*, vol. 72, no. 7, pp. 1265–1267, 2013.

F. Genre, R. López-Mejías, J. A. Miranda-Filloy et al., “Asymmetric dimethylarginine serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy,” *Clinical and Experimental Rheumatology*, vol. 31, no. 5, pp. 749–755, 2013.

F. Genre, R. López-Mejías, J. A. Miranda-Filloy et al., “Correlation between two biomarkers of atherosclerosis, osteopontin and angiopoietin-2, in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy,” *Clinical and Experimental Rheumatology*, vol. 32, no. 2, pp. 231–236, 2014.

F. Genre, R. López-Mejías, J. A. Miranda-Filloy, B. Carnero-López, I. Gómez-Acebo, and R. Blanco, “Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF-α therapy,” *Clinical and Experimental Rheumatology*, vol. 31, pp. 913–918, 2013.

F. Genre, R. López-Mejías, J. A. Miranda-Filloy, B. Ubilla, B. Carnero-López, and I. Gómez-Acebo, “Antitumour necrosis factor α treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients,” *Annals of the Rheumatic Diseases*, vol. 73, pp. 941–943, 2014.

J. A. Miranda-Filloy, J. Llorca, B. Carnero-López, C. González-Juanatey, R. Blanco, and M. A. González-Gay, “TNF-alpha antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients,” *Clinical and Experimental Rheumatology*, vol. 30, no. 6, pp. 850–855, 2012.

C. González-Juanatey, T. R. Vazquez-Rodriguez, J. A. Miranda-Filloy et al., “The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease,” *Medicine*, vol. 88, no. 6, pp. 358–365, 2009.

C. González-Juanatey, J. Llorca, J. A. Miranda-Filloy et al., “Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors,” *Arthritis Care & Research*, vol. 57, no. 2, pp. 287–293, 2007.

C. González-Juanatey, J. Llorca, E. Amigo-Díaz, T. Dierßen, J. Martin, and M. A. González-Gay, “High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors,” *Arthritis Care & Research*, vol. 57, no. 6, pp. 1074–1080, 2007.

S. M. Szabo, A. R. Levy, S. R. Rao et al., “Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study,” *Arthritis and Rheumatism*, vol. 63, no. 11, pp. 3294–3304, 2011.

M. J. Peters, I. E. van der Horst-Bruinsma, B. A. Dijkmans, and M. T. Nurmohamed, “Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis,” *Seminars in Arthritis and Rheumatism*, vol. 34, no. 3, pp. 585–592, 2004.

Y. S. Kim, Y. K. Sung, C. B. Choi et al., “The major determinants of arterial stiffness in Korean patients with rheumatoid arthritis are age and systolic blood pressure, not disease-related factors,” *Rheumatology International*, vol. 32, no. 11, pp. 3455–3461, 2012.

S. E. Gabriel and C. S. Crowson, “Risk factors for cardiovascular disease in rheumatoid arthritis,” *Current Opinion in Rheumatology*, vol. 24, no. 2, pp. 171–176, 2012.

J. Willers and A. Hahn, “Cardiovascular risk in patients with rheumatoid arthritis: assessment of several traditional risk parameters and a German risk score model,” *Rheumatology International*, vol. 32, no. 12, pp. 3741–3749, 2012.

P. H. Dessein, G. R. Norton, B. I. Joffe, A. T. Abdool-Carrim, A. J. Woodwiss, and A. Solomon, “Metabolic cardiovascular risk burden and atherosclerosis in African black and Caucasian women with rheumatoid arthritis: a cross-sectional study,” *Clinical and Experimental Rheumatology*, vol. 31, no. 1, pp. 53–61, 2013.

T. E. Toms, V. F. Panoulas, and G. D. Kitas, “Dyslipidaemia in rheumatological autoimmune diseases,” *Open Cardiovascular Medicine Journal*, vol. 5, pp. 64–75, 2011.

B. Seriolo, S. Accardo, D. Fasciolo, S. Bertolini, and M. Cutolo, “Lipoproteins, anticardiolipin antibodies and thrombotic events in rheumatoid arthritis,” *Clinical and Experimental Rheumatology*, vol. 14, no. 6, pp. 593–599, 1996.

H.-J. Priebe, “The aged cardiovascular risk patient,” *British Journal of Anaesthesia*, vol. 85, no. 5, pp. 763–778, 2000.

O. Ortega-Hernandez, R. Pineda-Tamayo, A. L. Pardo, A. Rojas-Villarraga, and J. Anaya, “Cardiovascular disease is associated with extra-articular manifestations in patients with rheumatoid arthritis,” *Clinical Rheumatology*, vol. 28, no. 7, pp. 767–775, 2009.

S. S. McCoy, C. S. Crowson, S. E. Gabriel, and E. L. Matteson, “Hypothyroidism as a risk factor for development of cardiovascular disease in patients with rheumatoid arthritis,” *Journal of Rheumatology*, vol. 39, no. 5, pp. 954–958, 2012.

G. E. Grems and G. Ferraccioli, “The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular disease,” *Autoimmunity Reviews*, vol. 10, no. 10, pp. 582–589, 2011.

O. Karadag, M. Calguneri, E. Atalar et al., “Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients,” *Clinical Rheumatology*, vol. 26, no. 5, pp. 695–699, 2007.

O. I. Galituina and O. V. Bychak, “Relationship of silent myocardial ischaemia with the course of rheumatoid arthritis and hyperhomocysteinemia,” *Litar'ka Sprava/Ministerstvo okhorony zdorov'ia Ukra¨ıny*, no. 1–2, pp. 48–52, 2011.
N. Sattar, D. W. McCarey, H. Capell, and I. B. McInnes, H. J. I. de Jong, R. J. Vandel, S. R. F. Salde et al., “Angiotensin-2 receptors and the risk of developing rheumatoid arthritis,” *Annals of the Rheumatic Diseases*, vol. 66, no. 2, pp. 116–120, 2007.

J. M. A. Lopez-Olivo, L. Gonzalez-Lopez, A. Garcia-Gonzalez et al., “Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis,” *Seminars in Arthritis and Rheumatism*, vol. 41, no. 4, pp. 535–544, 2012.

R. M. R. Pereira, J. E. de Carvalho, and E. Bonfá, “Metabolic syndrome in rheumatological diseases,” *Autoimmunity Reviews*, vol. 8, pp. 415–419, 2009.

M. Vadacca, D. Margiotta, A. Rigon et al., “Adipokines and systemic lupus erythematosus: relationship with metabolic syndrome and cardiovascular disease risk factors,” *Journal of Rheumatology*, vol. 36, no. 2, pp. 295–297, 2009.

V. R. da Cunha, C. V. Brenol, J. C. T. Brenol et al., “Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity,” *Scandinavian Journal of Rheumatology*, vol. 41, no. 3, pp. 186–191, 2012.

A. Zonana-Nacach, E. Santana-Sahagún, F. J. Jiménez-Balderas, and A. Camargo-Coronel, “Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus,” *Journal of Clinical Rheumatology*, vol. 14, no. 2, pp. 74–77, 2008.

C. Turesson and E. L. Matteson, “Cardiovascular risk factors, fitness and physical activity in rheumatic diseases,” *Current Opinion in Rheumatology*, vol. 19, no. 2, pp. 190–196, 2007.

V. F. Panoulas, K. M. J. Douglas, H. J. Milioni et al., “Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis,” *Rheumatology*, vol. 46, no. 9, pp. 1477–1482, 2007.

J. Mikdashi, B. Handwerger, P. Langenberg, M. Miller, and S. Kittner, “Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus,” *Stroke*, vol. 38, no. 2, pp. 281–285, 2007.

J. H. Kang, J. J. Keller, and H. C. Lin, “Outcomes of nonstenting percutaneous coronary intervention in patients with rheumatoid arthritis,” *American Journal of Cardiology*, vol. 109, no. 8, pp. 1160–1163, 2012.

J.-H. Kang, J. J. Keller, Y.-K. Lin, and H.-C. Lin, “A population-based case-control study on the association between rheumatoid arthritis and deep vein thrombosis,” *Journal of Vascular Surgery*, vol. 56, no. 6, pp. 1642–1648, 2012.

H. J. de Jong, R. J. Vandebriel, S. R. F. Saldi et al., “Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users,” *Pharmacoepidemiology and Drug Safety*, vol. 21, no. 8, pp. 835–843, 2012.

C. Fan, Z. Zhang, Y. Mei, C. Wu, and B. Shen, “Impaired brachial artery flow-mediated dilation and increased carotid intima-media thickness in rheumatoid arthritis patients,” *Chinese Medical Journal*, vol. 125, no. 5, pp. 832–837, 2012.

H. Maradit-Kremers, P. J. Nicola, C. S. Crowson, K. V. Ballman, and S. E. Gabriel, “Cardiovascular death in rheumatoid arthritis: a population-based study,” *Arthritis and Rheumatism*, vol. 52, no. 3, pp. 722–732, 2005.

S.-Y. Bang, K.-H. Lee, S.-K. Cho, H.-S. Lee, K. W. Lee, and S.-C. Bae, “Smoking increases rheumatoid arthritis susceptibility in individuals carrying the HLA-DRB1 shared epitope, regardless of rheumatoid factor or anti-cyclic citrullinated peptide antibody status,” *Arthritis & Rheumatism*, vol. 62, no. 2, pp. 369–377, 2010.

T. M. Farragher, N. J. Goodson, H. Naseem et al., “Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis,” *Arthritis and Rheumatism*, vol. 58, no. 2, pp. 359–369, 2008.

M. A. Gonzalez-Gay, C. Gonzalez-Juanatey, M. J. Lopez-Diaz et al., “HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis,” *Arthritis Care and Research*, vol. 57, no. 1, pp. 125–132, 2007.

M. A. Gonzalez-Gay, C. Gonzalez-Juanatey, and W. E. Ollier, “Endothelial dysfunction in rheumatoid arthritis: influence of HLA-DRB1 alleles,” *Autoimmunity Reviews*, vol. 3, no. 4, pp. 301–304, 2004.

C. Turesson, W. M. O’Fallon, C. S. Crowson, S. E. Gabriel, and E. L. Matteson, “Occurrence of extraarticular disease manifestations is associated with excess mortality in a community-based cohort of patients with rheumatoid arthritis,” *Journal of Rheumatology*, vol. 29, no. 1, pp. 62–67, 2002.

C. Turesson, R. L. McClelland, T. J. H. Christianson, and E. L. Matteson, “Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis,” *The Annals of the Rheumatic Diseases*, vol. 66, no. 1, pp. 70–75, 2007.

C. Gonzalez-Juanatey, A. Testa, A. Garcia-Castelo et al., “HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis,” *American Journal of Medicine*, vol. 114, no. 8, pp. 647–652, 2003.

D. L. Mattey, W. Thomson, W. E. R. Ollier et al., “Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the early rheumatoid arthritis study,” *Arthritis and Rheumatism*, vol. 56, no. 5, pp. 1408–1416, 2007.

R. Palomino-Morales, C. Gonzalez-Juanatey, T. R. Vazquez-Rodriguez et al., “A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis,” *Arthritis Research and Therapy*, vol. 12, no. 2, article R71, 2010.

L. Rodriguez-Rodriguez, C. Gonzalez-Juanatey, R. Palomin-Morales et al., “TNF-A308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis,” *Atherosclerosis*, vol. 216, pp. 125–130, 2011.

R. López-Mejías, M. García-Bermúdez, C. González-Juanatey et al., “NFKB1-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis,” *Atherosclerosis*, vol. 224, pp. 426–429, 2012.

T. E. Toms, V. F. Panoulas, J. P. Smith et al., “Rheumatoid arthritis susceptibility genes associate with lipid levels in patients with rheumatoid arthritis,” *Annals of the Rheumatic Diseases*, vol. 70, no. 6, pp. 1025–1032, 2011.
A. M. El-Barbary, E. M. Kassem, M. A. S. El-Sergany, S. F. J. López-Longo, D. Oliver-Miñarro, I. del Torre et al., “Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide,” Journal of Rheumatology, vol. 38, no. 5, pp. 828–834, 2011.

J. Trifunovic Cvetkovic, S. Wällberg-Jonsson, B. Stegmayr, S. J. Wang, B. Hu, Y. Meng, C. Zhang, K. Li, and C. Hui, “The clinical manifestations of rheumatoid arthritis are associated with elevated anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis,” Arthritis & Rheumatism, vol. 61, pp. 419–424, 2009.

D. Marasovic-Krstulovic, D. Martinovic-Kaliterna, D. Fabijanic, and J. Morovic-Vrges, “Are the anti-cyclic citrullinated peptide antibodies independent predictors of myocardial involvement in patients with active rheumatoid arthritis?” Rheumatology, vol. 50, no. 8, pp. 1505–1512, 2011.

D. L. Mattey, P. T. Dawes, N. B. Nixon, L. Goh, M. J. Banks, and G. D. Kitas, “Increased levels of antibodies to cyto keratin 18 in patients with rheumatoid arthritis and ischaemic heart disease,” Annals of the Rheumatic Diseases, vol. 63, no. 4, pp. 420–425, 2004.

M. J. L. Peters, V. P. van Halm, M. T. Nurmohamed et al., “Relations between autoantibodies against oxidized low-density lipoprotein, inflammation, subclinical atherosclerosis, and cardiovascular disease in rheumatoid arthritis,” Journal of Rheumatology, vol. 35, no. 8, pp. 1495–1499, 2008.

Y. Sherer, R. Gerli, B. Gilburd et al., “Thickened carotid artery intima-media in rheumatoid arthritis is associated with elevated anticolipin antibodies,” Lupus, vol. 16, no. 4, pp. 259–264, 2007.

V. N. Vuilleumier, S. Bas, S. Pagano et al., “Anti-apolipoprotein A-I IgG predicts major cardiovascular events in patients with rheumatoid arthritis,” Arthritis and Rheumatism, vol. 62, no. 9, pp. 2640–2650, 2010.

N. Vuilleumier, J. Britt, R. Alizadeh, T. Jegendra, I. Hafrström, and J. Frostegärd, “Anti-apolipoprotein A-I IgG and oxidized LDL are raised in rheumatoid arthritis (RA): potential associations with cardiovascular disease and RA disease activity,” Scandinavian Journal of Rheumatology, vol. 39, no. 6, pp. 447–453, 2010.

E. Walewska, R. Rupinski, A. Filipowicz-Sosnowska, and B. Wojciechowska, “Follow-up studies of rheumatoid arthritis patients with the presence of antiphospholipid antibodies,” Polskie Archiwum Medycyny Wewnętrznej, vol. 115, pp. 438–442, 2006.
M. M. Mabrouk, M. A. Ghazy, and T. M. Hassan, “Serum pentraxin 3 and interleukin-6 are associated with subclinical atherosclerosis in recent-onset rheumatoid arthritis,” The Egyptian journal of immunology, vol. 17, no. 1, pp. 87–99, 2010.

P. A. Mac Mullan, A. J. Peace, A. M. Madigan, A. F. Tedesco, D. Kenny, and G. M. McCarthy, “Platelet hyper-reactivity in active inflammatory arthritis is unique to the adenosine diphosphate pathway: a novel finding and potential therapeutic target,” Rheumatology, vol. 49, no. 2, pp. 240–245, 2010.

M. A. Abdel-Khalek, A. M. El-Barbary, S. A. Essa, and A. S. Ghabashi, “Serum hepcidin: a direct link between anemia of inflammation and coronary artery atherosclerosis in patients with rheumatoid arthritis,” Journal of Rheumatology, vol. 38, no. 10, pp. 2153–2159, 2011.

S. Abou-Raya, A. Abou-Raya, A. Naim, and H. Abuelkheir, “Rheumatoid arthritis, periodontal disease and coronary artery disease,” Clinical Rheumatology, vol. 27, no. 4, pp. 421–427, 2008.

Y. Asanuma, C. P. Chung, A. Oeser et al., “Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis,” Atherosclerosis, vol. 195, no. 2, pp. e135–e141, 2007.

L. Bazzichi, L. Ghiadoni, A. Rossi et al., “Osteopontin is associated with increased arterial stiffness in rheumatoid arthritis,” Molecular Medicine, vol. 15, no. 11-12, pp. 402–406, 2009.

A. Elkan, N. Häkansson, J. Frostegård, T. Cederholm, and I. Hafström, “Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study,” Arthritis Research and Therapy, vol. 11, no. 2, article R37, 2009.

A. McIntegart, H. A. Capell, D. Creran, A. Rumley, M. Woodward, and G. D. O. Lowe, “Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis,” Rheumatology, vol. 40, no. 6, pp. 640–644, 2001.

V. F. Panoulas, K. M. J. Douglas, H. J. Milionis et al., “Serum uric acid is independently associated with hypertension in patients with rheumatoid arthritis,” Journal of Human Hypertension, vol. 22, no. 3, pp. 177–182, 2008.

K. Tanaka, M. Inaba, H. Goto et al., “Paraarticular trabecular bone loss at the ultradistal radius and increased arterial stiffening in postmenopausal patients with rheumatoid arthritis,” Journal of Rheumatology, vol. 33, no. 4, pp. 652–658, 2006.

L. N. Troelsen, P. Garred, B. Christiansen et al., “Double role of mannose-binding lectin in relation to carotid intima-media thickness in patients with rheumatoid arthritis,” Molecular Immunology, vol. 47, no. 4, pp. 713–718, 2010.

S. Wällberg-Jonsson, G. H. Dahlen, T. K. Nilsson, M. Rånbö, and S. Rantapää-Dahlqvist, “Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis,” Clinical Rheumatology, vol. 12, no. 3, pp. 318–324, 1993.

A. Stavropoulos-Kalinoglou, G. S. Metsios, Y. Koutetakdakis et al., “Redefining overweight and obesity in rheumatoid arthritis patients,” Annals of the Rheumatic Diseases, vol. 66, no. 10, pp. 1316–1321, 2007.

G. D. Summers, G. S. Metsios, A. Stavropoulos-Kalinoglou, and G. D. Kitas, “Rheumatoid cachexia and cardiovascular disease,” Nature Reviews Rheumatology, vol. 6, no. 8, pp. 445–451, 2010.

V. Bellomio, A. Spindler, E. Lucero et al., “Systemic lupus erythematosus: mortality and survival in Argentina. A multicenter study,” Lupus, vol. 9, no. 5, pp. 377–381, 2000.
cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among ‘Hispanics,’ Medicine, vol. 83, no. 1, pp. 1–17, 2004.

[361] G. J. Pons-Estel, L. A. González, J. Zhang et al., “Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LVIII), a multiethnic US cohort,” Rheumatology, vol. 48, no. 7, pp. 817–822, 2009.

[362] H. Zaldívar-Alcántara, LE. Herrera-Jiménez, E. Dehesa-López, and R. Correa-Rotter, “Risk factors for the development of thrombotic complication in patients with lupus erythematosus and lupus nephropathy,” Revista de Investigacion Clinica, vol. 65, pp. 199–208, 2013.

[363] M. McMahon, B. J. Skagg, L. Sahakian et al., “High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids,” Annals of the Rheumatic Diseases, vol. 70, no. 9, pp. 1619–1624, 2011.

[364] M. McMahon, J. Grossman, B. Skagg et al., “Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 60, no. 8, pp. 2428–2437, 2009.

[365] A. C. Travassos, M. C. Rocha, S. Souza, C. Brandão, and J. F. Silva, “Frequência dos anticorpos antifosfolipídeos (aFL) em portadores de lupus eritematoso sistêmico (LES) no Estado da Bahia,” Revista Brasileira de Reumatologia, vol. 40, pp. 183–188, 2000.

[366] E.Alexanderson, J. M. Ochoa, R. Calleja et al., “Endothelial dysfunction in systemic lupus erythematosus: evaluation with 13N-ammonia PET,” Journal of Nuclear Medicine, vol. 51, pp. 1927–1931, 2010.

[367] R. W. Telles, C. C. D. Lanna, G. A. Ferreira, and M. A. P. de Cardvalho, “Frequência de doença cardiovascular aterosclerótica e de seus fatores de risco em pacientes com lúpus eritematoso sistêmico,” Revista de Investigacion Clinica, vol. 47, pp. 165–173, 2007.

[368] C. R. L. Cardoso, F. V. Signorelli, J. A. Papi, and G. F. Salles, “Prevalence and factors associated with dyslipidemia in Brazilian systemic lupus erythematosus patients,” Rheumatology International, vol. 28, no. 4, pp. 323–327, 2008.

[369] A. W. Silva de Souza, F. Satomi Hatta, F. Miranda Jr., and E. Inoue Sato, “Atherosclerotic plaque in carotid arteries in systemic lupus erythematosus: Frequency and associated risk factors,” Sao Paulo Medical Journal, vol. 123, no. 3, pp. 137–142, 2005.

[370] S. M. A. Toloza, J. M. Roseman, G. S. Alarcón et al., “Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage,” Arthritis and Rheumatism, vol. 50, no. 10, pp. 3177–3186, 2004.

[371] A. Zonana-Nacach, A. Camargo-Coronel, P. Yáñez et al., “Measurement of damage in 210 Mexican patients with systemic lupus erythematosus: relationship with disease duration,” Lupus, vol. 7, no. 2, pp. 119–123, 1998.

[372] M. A. B. Lozovoy, A. N. C. Simão, M. S. N. Hohmann et al., “Inflammatory biomarkers and oxidative stress measurements in patients with systemic lupus erythematosus with or without metabolic syndrome,” Lupus, vol. 20, no. 13, pp. 1356–1364, 2011.

[373] A. M. Negrán, M. J. Molina, A. M. Mayor, V. E. Rodríguez, and L. M. Vilá, “Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico,” Lupus, vol. 17, no. 4, pp. 348–354, 2008.

[374] S.-Y. Liu, L.-S. Han, J.-Y. Guo et al., “Metabolic syndrome in Chinese patients with systemic lupus erythematosus: no association with plasma cortisol level,” Lupus, vol. 22, no. 5, pp. 519–526, 2013.

[375] M. J. Ormseth, L. L. Swift, S. Fazio et al., “Free fatty acids are associated with metabolic syndrome and insulin resistance but not inflammation in systemic lupus erythematosus,” Lupus, vol. 22, no. 1, pp. 26–33, 2013.

[376] T. A. Gheita, H. A. Raafat, S. Sayed, H. El-Fishawy, M. M. Nasrallah, and E. Abdel-Rasheed, “Metabolic syndrome and insulin resistance comorbidity in systemic lupus erythematosus—effect on carotid intima-media thickness,” Zeitschrift für Rheumatologie, vol. 72, no. 2, pp. 172–177, 2013.

[377] S. Liu, J. Guo, L. Zhang et al., “[Incidence of metabolic syndrome in systemic lupus erythematosus and its influence by glucocorticoids],” Zhonghua Nei Ke Za Zhi, vol. 51, no. 6, pp. 441–444, 2012.

[378] F. D. M. M. dos Santos, M. C. Borges, M. I. T. D. Correia, R. W. Telles, and C. C. D. Lanna, “Assessment of nutritional status and physical activity in systemic lupus erythematosus patients,” Revista Brasileira de Reumatologia, vol. 50, no. 6, pp. 631–645, 2010.

[379] C. R. L. Cardoso, M. A. O. Sales, J. A. S. Papi, and G. F. Salles, “QT-interval parameters are increased in systemic lupus erythematosus patients,” Lupus, vol. 14, no. 10, pp. 846–852, 2005.

[380] A. Rizk, T. A. Gheita, S. Nassef, and A. Abdallah, “The impact of obesity in systemic lupus erythematosus on disease parameters, quality of life, functional capacity and the risk of atherosclerosis,” International Journal of Rheumatic Diseases, vol. 15, no. 3, pp. 261–267, 2012.

[381] K. T. Ho, C. W. Ahn, G. S. Alarcón et al., “Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events,” Rheumatology, vol. 44, no. 10, pp. 1303–1307, 2005.

[382] A. J. Szalai, G. S. Alarcón, J. Calvo-Alén et al., “Systemic lupus erythematosus in a multiethnic US Cohort (LUMINA). XXX: Association between C-reactive protein (CRP) gene polymorphisms and vascular events,” Rheumatology, vol. 44, no. 7, pp. 864–867, 2005.

[383] B. F. A. Freire, R. C. da Silva, A. T. Fabro, and D. C. dos Santos, “Is systemic lupus erythematosus a new risk factor for atherosclerosis?” Arquivos Brasileiros de Cardiologia, vol. 87, no. 3, pp. 300–306, 2006.

[384] S. Haque, C. Rakieh, F. Marriage et al., “Brief report: shortened telomere length in patients with systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 65, no. 5, pp. 1319–1323, 2013.

[385] C. Maric-Bilik, E. L. Gilbert, and M. J. Ryan, “Impact of ovarian function on cardiovascular health in women: focus on hypertension,” International Journal of Women’s Health, vol. 6, pp. 131–139, 2014.

[386] L. R. Sammaritano, “Menopause in patients with autoimmune diseases,” Autoimmunity Reviews, vol. 11, no. 6–7, pp. A430–A436, 2012.

[387] L. Onetti, S. Villaefe, E. Menzo et al., “Hyperhomocysteinemia as a thrombotic risk factor in patients suffering from systemic lupus erythematosus and antiphospholipid syndrome,” Revista de la Facultad de Ciencias Médicas, vol. 62, no. 3, pp. 19–23, 2005.

[388] G. J. Pons-Estel, V. Saurit, G. S. Alarcón et al., “The impact of rural residency on the expression and outcome of systemic lupus erythematosus: data from a multiethnic Latin American cohort,” Lupus, vol. 21, no. 13, pp. 1397–1404, 2012.
microparticle release via a nonmuscle myosin II motor protein-dependent pathway,” *Blood*, vol. 122, pp. 3808–3817, 2013.

[418] K. Veres, G. Lakos, A. Kerényi et al., “Antiphospholipid antibodies in acute coronary syndrome,” *Lupus*, vol. 13, no. 6, pp. 423–427, 2004.

[419] J. George, D. Harats, B. Gilburd et al., “Immunolocalization of β2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression,” *Circulation*, vol. 99, no. 17, pp. 2227–2230, 1999.

[420] R. Gerli, E. Bartoloni Bocci, G. Vaudo, S. Marchesi, C. Vitali, and Y. Shoenfeld, “Traditional cardiovascular risk factors in primary Sjögren’s syndrome—role of dyslipidaemia,” *Rheumatology*, vol. 45, no. 12, pp. 1580–1582, 2006.

[421] G. Lippi, P. Caramaschi, M. Montagna, G. L. Salvagno, A. Volpe, and G. Guidi, “Lipoprotein[a] and the lipid profile in patients with systemic sclerosis,” *Clinica Chimica Acta*, vol. 364, no. 1-2, pp. 345–348, 2006.

[422] M. M. Cerinic, G. Valentini, G. G. Sorano et al., “Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis,” *Seminars in Arthritis and Rheumatism*, vol. 32, no. 5, pp. 285–295, 2003.

[423] E. F. Borba, C. T. L. Borges, and E. Bonfá, “Lipoprotein profile in limited systemic sclerosis,” *Rheumatology International*, vol. 25, pp. 379–383, 2005.

[424] N. Tsifetaki, A. N. Georgiadis, Y. Alamano, S. Fanis, M. I. Argyropoulou, and A. A. Drosos, “Subclinical atherosclerosis in scleroderma patients,” *Scandinavian Journal of Rheumatology*, vol. 39, no. 4, pp. 326–329, 2010.

[425] A. L. Herrick, K. J. Illingworth, S. Hollis, J. M. Gomez-Zumaquero, and F. J. Tinahones, “Antibodies against oxidized low-density lipoproteins in systemic sclerosis,” *Rheumatology*, vol. 40, no. 4, pp. 401–405, 2001.

[426] U. Nussinovitch and Y. Shoenfeld, “Autoimmunity and heart diseases: pathogenesis and diagnostic criteria,” *Archivum Immunologicum et Therapiae Experimentalis*, vol. 57, no. 2, pp. 95–104, 2009.

[427] L. R. Lopez, D. F. Simpson, B. L. Hurley, and E. Matsuura, “OxLDL/β2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement,” *Annals of the New York Academy of Sciences*, vol. 1051, pp. 313–322, 2005.

[428] M. Kodera, I. Hayakawa, K. Komura et al., “Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations,” *Journal of Rheumatology*, vol. 32, no. 4, pp. 629–636, 2005.

[429] O. Timár, P. Soltész, S. Szamosi et al., “Increased arterial stiffness as the marker of vascular involvement in systemic sclerosis,” *The Journal of Rheumatology*, vol. 35, pp. 1329–1333, 2008.